Tag Archives: MOFCOM

Greater Bay Area 2026: mutual recognition progress for Hong Kong and Macao professionals practising north

  • The GBA lawyer pilot has issued 646 practicing certificates (544 Hong Kong, 102 Macao) and covers all nine mainland GBA cities, with the pilot currently due to expire on 4 October 2026.
    大湾区律师执业试点已发出 646 张执业证书(香港 544、澳门 102),覆盖内地九市,试点目前将于 2026 年 10 月 4 日到期。
  • The 2026 GBA lawyer examination runs online registration (16–25 April), legal-training, and a written exam on 19 September in Shenzhen and Zhuhai.
    2026 年粤港澳大湾区律师执业考试实行网上报名(4 月 16–25 日)、法律知识培训与 9 月 19 日深圳珠海笔试。
  • Physician recognition under CEPA has produced 951 Hong Kong/Macao doctors with Mainland qualifications and 277 short-term practitioners, supported by a ten-point facilitation package.
    CEPA 框架下医师便利化已形成 951 名取得内地资格的港澳医生与 277 名短期执业者,并配套十条便利措施。
  • Tax agents from Hong Kong and Macao may practise in Qianhai–Shekou without an examination, by registration, and may even establish jointly-run tax-agent firms.
    港澳涉税专业人士可在前海蛇口免考试、以执业登记方式执业,并可发起设立联营税务师事务所。
  • Nansha’s 2.0 overseas professional-qualification list covers 248 qualifications (112 from Hong Kong/Macao/Taiwan) and introduces a “practise first, file later” model.
    南沙 2.0 版境外职业资格认可清单覆盖 248 项资格(含港澳台 112 项),并推出”先执业后备案”模式。
  • Foreign-invested firms should track the October 2026 pilot expiry and the possible elevation of the lawyer pilot into a permanent institution.
    外资企业应当关注 2026 年 10 月的试点到期节点,以及律师试点可能上升为法律制度安排的走向。
  • Recognised professionals still need the underlying Mainland entity, licence and social-insurance coordination before they can deliver services in Guangdong.
    获认可专业人士仍需在广东具备 underlying 内地主体、执业许可与社保衔接,方能实际提供服务。

Greater Bay Area 2026: mutual recognition progress for Hong Kong and Macao professionals practising north | 2026 大湾区:港澳专业人才北上执业资格互认进展

Overview

A recurring bottleneck for foreign-invested and Hong Kong/Macao-invested businesses in the Greater Bay Area (GBA) is talent: can the professionals they rely on — lawyers, doctors, tax agents — actually practise north of the border? The 2026 picture is one of steady, pragmatic liberalisation concentrated in three professions, each with its own mechanism. Lawyers move through a statutory pilot with an expiry date; lawyers’ recognition is the most advanced and most politicised. Doctors move through CEPA-based facilitation and the “Hong Kong/Macao medicine pass”. Tax agents move through a Qianhai–Shekou pilot that has already removed the examination barrier.

This article takes stock of where each profession stands in 2026, what the remaining conditions are, and what foreign-invested enterprises should watch.

Lawyers: a mature pilot facing a sunset clause

The GBA lawyer pilot originated from an August 2020 NPC Standing Committee authorisation allowing Hong Kong legal practitioners and Macao lawyers to obtain Mainland practicing qualifications and practise in the nine GBA mainland cities. A September 2023 decision extended the pilot by three years to 4 October 2026.

According to the State Council report deliberated at the 23rd session of the 14th NPC Standing Committee in June 2026, the Ministry of Justice has organised five GBA lawyer examinations; more than 2,000 Hong Kong and Macao lawyers registered, and 646 obtained the GBA lawyer certificate — 544 Hong Kong legal practitioners and 102 Macao lawyers. Geographically they cover all nine cities: Guangzhou 166, Shenzhen 351, Zhuhai 58, Foshan 13, Huizhou 11, Dongguan 19, Zhongshan 16, Jiangmen 6, Zhaoqing 6. Of the 646, 81 serve as arbitrators at Mainland arbitration institutions, 71 as commercial mediators, and 26 as specially-invited mediators at Guangdong courts. They practise in 190 law firms, including 106 in HK/Macao–Mainland joint-venture firms and 540 in Mainland firms.

The 2026 examination follows a clear calendar. The Ministry of Justice announcement (30 March 2026) sets online registration from 16 to 25 April, a compulsory legal-knowledge training before the exam, and the written test on 19 September in Shenzhen and Zhuhai. Two papers (objective and subjective) total 200 points; results and the pass line are published by January 2027.

A critical uncertainty is the 4 October 2026 sunset. The report notes broad support for elevating the pilot into an institutional arrangement, and stakeholders are watching whether it is extended again or codified.

Doctors: CEPA facilitation and the medicine pass

Medical recognition is broader but more layered. Under CEPA, Guangdong has rolled out a ten-point facilitation package for Hong Kong and Macao doctors — “short-term practice + multi-site practice + Hong Kong/Macao medicine pass + professional-title recognition”. By 2025, 95 Macao nursing graduates had passed the national nurse exam in Guangdong, 73 Hong Kong/Macao talents obtained professional-title assessments, 951 Hong Kong/Macao doctors had obtained Mainland physician qualifications and practise, and 277 practise short-term. Fifty Hong Kong/Macao-invested medical institutions operate in Guangdong.

For individual doctors, the Hong Kong/Macao physician qualification recognition (clinical, dental; TCM via the provincial TCM bureau) requires, among other things, lawful practice qualification in Hong Kong/Macao for at least five years before 31 December 2007, a specialist certificate, and current practice in a Hong Kong/Macao medical institution. The Guangdong government service portal shows an eight-working-day commitment for the recognition, fully online.

The “Hong Kong/Macao medicine pass” (港澳药械通) complements physician mobility: it lets specified Mainland GBA hospitals use drugs and devices already approved in Hong Kong/Macao, so a Hong Kong specialist can treat cross-boundary patients with familiar products. As of late April 2026, the pass covered 162 approved innovative drugs/devices (71 drugs, 91 devices) across 71 designated hospitals in all nine cities, serving over 17,000 patient-visits.

Tax agents: the Qianhai–Shekou breakthrough

The least visible but most procedurally radical change is for tax agents. The *Interim Measures for Hong Kong and Macao Tax Professionals Practising in the China (Guangdong) FTZ Shenzhen Qianhai–Shekou Area*, revised and issued by the Shenzhen Tax Bureau, removed the practice examination, widened eligibility from Hong Kong tax agents to Hong Kong and Macao tax professionals, dropped the 180-day practice requirement, and allowed them to establish tax-agent firms (treated as Mainland tax agents as shareholders). Registration, not examination, is the gateway.

The results are concrete: the first Hong Kong/Macao-invested tax-agent firm (Guozheng Zhengzheng) was established in Shenzhen in 2021, and the first tripartite Shenzhen–Hong Kong–Macao joint tax-agent firm (Hua Meng Ling Jun Liu Guo) was registered in Qianhai in November 2021. As of recent figures, 74 Hong Kong/Macao tax professionals have completed cross-boundary practice registration and 7 joint-venture tax-agent firms are administratively registered and operating. Supporting measures — the “18 measures for innovation in Qianshui tax-related services” and “15 measures to boost the Qianhai tax-service cluster” — have drawn the first batch of over 30 well-known tax institutions to the cluster.

Nansha’s recognition list and “practise first, file later”

Beyond the three professions, Nansha has built a broad recognition channel. Its 2.0 overseas professional-qualification list (issued January 2026) covers 248 foreign qualifications (112 from Hong Kong/Macao/Taiwan) and pairs with the *Nansha Measures for Hong Kong/Macao Professional Institutions and Professionals*. The standout innovation is “practise first, file later”: a Hong Kong/Macao-registered institution or individual with recognised qualifications may provide professional services in engineering, urban planning and medical fields in Nansha and complete confirmation within one month after practise. Nansha also recognises Hong Kong’s MPF and Macao’s social-security fund as equivalent, exempting dual social-insurance contributions for qualifying residents.

Practical implications for foreign-invested enterprises

  • Legal counsel: a foreign-invested enterprise with GBA disputes can now retain a GBA-licensed Hong Kong or Macao lawyer directly, and should brief counsel on the 4 October 2026 pilot horizon when planning multi-year engagements.
  • Medical cover: firms relocating staff to the GBA can leverage the medicine pass and cross-boundary medical facilities (e.g., the University of Hong Kong–Shenzhen Hospital) for international-standard care.
  • Tax and audit: Hong Kong/Macao-invested groups can use Qianhai-based joint tax-agent firms for integrated cross-boundary tax and audit, but must confirm the firm’s registration and the professional’s practise status.
  • Talent planning: track the lawyer-pilot sunset and the possible institutionalisation; otherwise build succession so key matters are not stranded if a licence lapses.
  • Entity and licence: recognition eases entry but does not eliminate the need for a compliant Mainland entity, local licence and social-insurance coordination.

Sources

Related reading

  • see also: GBA cross-border factor flows (article 134)
  • see also: GBA foreign-invested enterprise tax and landing (article 135)
  • see also: GBA healthcare foreign-investment opportunities (article 137)

2026 大湾区:港澳专业人才北上执业资格互认进展

概述

对外资与港澳资企业而言,粤港澳大湾区一个反复出现的瓶颈是人才:其所依赖的律师、医师、税务师能否真正跨过边境执业?2026 年的图景是务实、稳步的开放,集中于三个职业,各有机制。律师通过带有到期日的法定试点推进,其互认最成熟也最受关注;医师通过 CEPA 框架下的便利措施与”港澳药械通”流动;税务师则通过已取消考试门槛的前海蛇口试点。

本文盘点各行业 2026 年的进展、剩余条件,以及外资企业应关注的节点。

律师:成熟试点面临日落条款

大湾区律师试点源于 2020 年 8 月全国人大常委会授权,允许香港法律执业者、澳门执业律师在内地九市取得执业资质并执业;2023 年 9 月决定延长三年至 2026 年 10 月 4 日。

据 2026 年 6 月十四届全国人大常委会第二十三次会议审议的国务院报告,司法部已组织 5 次大湾区律师执业考试,2000 余名港澳律师报名,646 人取得大湾区律师执业证书——香港法律执业者 544 人、澳门执业律师 102 人。地域上覆盖九市:广州 166、深圳 351、珠海 58、佛山 13、惠州 11、东莞 19、中山 16、江门 6、肇庆 6。其中 81 人任内地仲裁机构仲裁员,71 人任商事调解员,26 人任广东各级法院特邀调解员;在 190 家律所执业,其中 106 人在港澳与内地合伙联营所、540 人在内地所。

2026 年考试日程清晰。司法部 3 月 30 日公告确定网上报名 4 月 16–25 日、考前须参加法律知识培训、9 月 19 日于深圳珠海笔试;两卷(客观+主观)共 200 分,成绩与合格线于 2027 年 1 月公布。

关键不确定性在 2026 年 10 月 4 日的日落节点。报告提到各方普遍希望将试点上升为法律制度安排,市场正关注其是否再次延期或立法固化。

医师:CEPA 便利与药械通

医师互认面更广但层级更多。CEPA 框架下,广东推出港澳医师执业便利化十条,形成”短期行医+多点执业+港澳药械通+职称认定”政策包。截至 2025 年,95 名澳门护理本科毕业生在粤通过国家护士考试,73 名港澳人才通过专业技术资格评审,951 名港澳籍医生取得内地医师资格并执业,277 名短期执业;港澳服务提供者在粤开设医疗机构 50 家。

对个体医生,港澳医师内地医师资格认定(临床、口腔;中医向省中医药局申请)要求,除其他条件外,2007 年 12 月 31 日前已取得港澳合法行医资格满 5 年、具专科医师资格证书并在港澳医疗机构执业。广东政务服务网显示该认定承诺 8 个工作日办结、全程网办。

“港澳药械通”与医师流动互补:它允许指定的内地大湾区医院使用已在港澳获批的药品与器械,使香港专科医生能以熟悉的产品跨境诊治。截至 2026 年 4 月底,药械通覆盖 71 家指定医院、162 款创新药械(71 药品、91 器械),惠及超 1.7 万人次。

税务师:前海蛇口的突破

最不显眼却程序上最激进的变化在税务师领域。深圳市税务局修订印发的《港澳涉税专业人士在中国(广东)自由贸易试验区深圳前海蛇口片区执业管理暂行办法》,取消执业考试,将适用从香港税务师扩展至香港、澳门涉税专业人士,取消 180 天执业天数要求,并允许其发起设立税务师事务所(视同内地税务师担任股东)。准入方式为执业登记而非考试。

成效具体:全国第一家港澳投资的税务师事务所(国正郑郑)2021 年在深圳设立,全国第一家深港澳联营税务师事务所(华盟灵均刘郭)2021 年 11 月在前海登记。据近期数据,已有 74 位港澳涉税专业人士完成跨境执业登记,7 家联营税务师事务所完成行政登记并实际运营。《前海涉税服务业集聚区十八条》与《助推前海涉税服务业集聚区建设十五项举措》已吸引首批 30 余家知名涉税机构签约入驻。

南沙的认可清单与”先执业后备案”

除三职业外,南沙构建了更宽的认可通道。其 2026 年 1 月发布的 2.0 版境外职业资格认可清单覆盖 248 项境外资格(含港澳台 112 项),配套《南沙区港澳专业机构和港澳专业人士执业实施办法》。突出创新是”先执业后备案”:取得港澳认可资质的机构和自然人,可在南沙工程建设、城市规划、医疗等领域提供服务,并在执业后 1 个月内完成确认。南沙还认可香港强积金、澳门社会保障基金为等效社保,对符合条件的港澳居民豁免重复参保。

对外资企业的实务启示

  • 法律顾问: 涉及大湾区争议的外资企业现在可直接聘请持大湾区执照的香港或澳门律师,并就 2026 年 10 月 4 日的试点节点,在多年期委托中提前规划。
  • 医疗覆盖: 搬迁员工至大湾区的企业,可借助药械通与跨境医疗机构(如香港大学深圳医院)获得国际水准诊疗。
  • 税务与审计: 港澳资集团可使用前海联营税务师事务所提供一体化跨境税务与审计,但须确认事务所登记状态与专业人士执业资格。
  • 人才规划: 关注律师试点日落及可能的制度化走向,否则应建立 succession,避免证照失效导致事务搁置。
  • 主体与许可: 互认降低准入门槛,但不免除合规的内地主体、本地许可与社保衔接要求。

来源

相关阅读

  • 见:大湾区跨境要素流动便利化(第 134 篇)
  • 见:大湾区外商独资企业落地与税收优惠(第 135 篇)
  • 见:大湾区医疗健康产业外资机会(第 137 篇)

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs

  • On 15 May 2026 the revised Implementation Regulations of the Drug Administration Law took effect, with Article 32 expressly allowing segmented (split-site) production of qualifying innovative drugs under a unified quality-assurance system.
    2026年5月15日,新修订的《药品管理法实施条例》施行,其中第三十二条明确允许符合条件的创新药在统一质量保证体系下分段委托生产。
  • The State Drug Administration has separately worked on biological-product segmented production; the 2026 Action Plan to Stabilise and Optimise Foreign Investment now calls for detailed rules for cross-border segmented production of both biologicals and chemical drugs.
    国家药监局已就生物制品分段生产单独发文推进;2026年《利用外资固稳促优行动方案》进一步提出研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • Segmented production applies to innovative drugs with special production-process or facility requirements, clinically urgent drugs, and drugs needed for public-health emergencies, as designated by the State Council.
    分段生产适用于生产工艺、设施设备有特殊要求的创新药,临床急需的药品,以及突发公共卫生事件急需或储备需要的药品等国务院规定情形。
  • The marketing authorisation holder (MAH) remains the single, final quality-responsible party and must build a unified quality-assurance system spanning all production sites.
    药品上市许可持有人(MAH)仍是唯一、最终的质量责任主体,必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系。
  • For foreign MAHs, the combination of segmented production and the FIE action plan opens a path to structure cross-border biologics and chemical manufacturing while keeping Chinese regulatory responsibility centralised.
    对外资MAH而言,分段生产与稳外资行动方案的组合,为跨境生物制品与化学药品生产布局开辟了路径,同时保持中国监管责任集中化。
  • Commercial insurers are also being encouraged to cover more innovative drugs and devices, and foreign-made drugs gain smoother entry into retail channels.
    政策同时鼓励保险公司将更多创新药械纳入商业保险保障范围,并便利外资企业生产的药品进入药品零售渠道。

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs | 中国药品分段生产:外资上市许可持有人的制造新选项

Why this matters now

Pharmaceutical manufacturing has traditionally meant one site, one product, one end-to-end process. China’s 2026 regulatory wave is deliberately unpicking that assumption. On 15 May 2026, the revised Implementation Regulations of the Drug Administration Law took effect, and Article 32 explicitly permits the segmented production of qualifying innovative drugs — where manufacturing steps run at different sites and potentially through different companies — as long as the marketing authorisation holder maintains a unified quality-assurance system. The move is paired with an explicit signal to foreign investors: the June 2026 Action Plan to Stabilise and Optimise Foreign Investment (issued by MOFCOM, NDRC and MOF) commits to detailed rules for cross-border segmented production of biological products and chemical drugs, building on the earlier biological-product segmented-production pilot. For a global pharma company with an approved innovative molecule, this changes how production for the Chinese market can be structured.

What segmented production covers

Article 32 of the revised Implementation Regulations permits segmented production for three categories: innovative drugs whose production process, equipment or facilities have special requirements; clinically urgent drugs requested by relevant State Council departments; and drugs needed for emergency response or stockpiling. The MAH may commission qualified production enterprises to handle separate production steps. Critically, the law does not decentralise responsibility: the MAH must establish a unified quality-assurance system covering the entire production process and all production sites, and remains the single final responsible party for product quality. The State Drug Administration’s inspection guidance for biological-product segmented production further requires the MAH to align quality-management systems across segment producers, apply quality-risk management to contamination and cross-contamination risks, and ensure the quality authorisation holder can base final release decisions on a full review of data from all segments.

The foreign-investment angle

The FIE Action Plan published in June 2026 explicitly says the authorities will move quickly to issue implementation rules for segmented production, to facilitate overseas drug marketing authorisation holders in carrying out cross-border segmented production of biologicals and chemical drugs. This is the first time the policy explicitly opens the door to cross-border arrangements — a Chinese plant handling one production step, an overseas site another. For foreign MAHs, the practical attraction is manufacturing flexibility: an API or biologic intermediate can be produced at the site with the best economics and IP-protection profile, with final formulation and packaging in China, while quality oversight remains anchored in one unified system. The same plan adds supporting measures: expanding the pilot scope for biotechnology and wholly foreign-owned hospitals, encouraging commercial insurers to cover more innovative drugs and devices, and easing foreign-made drugs into retail pharmacy channels.

Practical steps for foreign MAHs

  1. Map your portfolio. Identify molecules that qualify for segmented production — innovative drugs with special process or facility needs, clinically urgent products, or emergency/stockpile candidates.
  2. Decide the China anchor. Choose which production step will be performed in China and by which qualified manufacturer, and where the MAH quality-authorisation function will sit.
  3. Design the unified quality system. Draft the single quality-assurance framework covering all sites and segments, including technology transfer, change control, deviation handling and CAPA procedures.
  4. Engage the SDA early. Because implementation rules for chemical cross-border segmented production are still being drafted, use pre-submission consultation channels to align on expectations before committing investment.
  5. Review supply-chain economics. Model the tax, customs and logistics treatment of intermediates moving across borders, including bonded and duty-free options where available.
  6. Coordinate with insurance and retail access. Plan for how the product will reach patients — commercial insurance coverage and retail channel entry both affect market-access planning.

Risks and compliance notes

Segmented production is a permission, not a relaxation. The MAH’s single-responsibility rule means a failure at any segment is ultimately the MAH’s failure; contract manufacturers’ systems must be auditable and aligned. Foreign MAHs should also track the still-evolving implementation rules for chemical cross-border segmented production — until they issue, cross-border arrangements for small-molecule drugs should be structured conservatively. IP protection of process know-how across borders, GMP consistency between sites, and batch-release responsibilities all need contractual precision. Finally, the SDA’s on-site inspection and post-market supervision powers are unchanged, so documentation and traceability must satisfy the same standards as single-site production.


中国药品分段生产:外资上市许可持有人的制造新选项

为什么当下重要

药品生产传统上意味着”一个场地、一个产品、一条端到端流程”。中国2026年的监管浪潮正有意拆解这一假设。2026年5月15日,新修订的《药品管理法实施条例》施行,第三十二条明确允许符合条件的创新药分段生产——即制造环节在不同场地、甚至经由不同公司运行——只要上市许可持有人维护统一质量保证体系。该举措与对外资投资者的明确信号相配合:2026年6月商务部、国家发展改革委、财政部发布的《利用外资固稳促优行动方案》承诺研究出台生物制品与化学药品跨境分段生产实施细则,在早期生物制品分段生产试点基础上推进。对拥有获批创新分子的全球制药企业而言,这改变了中国市场的生产布局方式。

分段生产覆盖哪些情形

修订后《实施条例》第三十二条允许三类药品分段生产:生产工艺、设施设备有特殊要求的创新药;国务院有关部门提出的临床急需药品;以及应对突发公共卫生事件急需或储备需要的药品。MAH可以委托符合条件的生产企业承担不同生产步骤。关键在于,法律并未分散责任:MAH必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系,并作为产品质量唯一且最终的责任主体。国家药监局生物制品分段生产现场检查指南进一步要求MAH使各分段生产企业的质量管理体系有效衔接与统一,运用质量风险管理方法识别控制污染、交叉污染及差错风险,并确保质量受权人能基于对各分段数据的全面审核作出最终放行决定。

外资维度

2026年6月发布的稳外资行动方案明确提出,抓紧研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。这是政策首次明确为跨境安排敞开大门——中国工厂承担一个生产步骤,海外场地承担另一个。对外资MAH而言,实际吸引力在于制造灵活性:原料药或生物制品中间体可在经济性与知识产权保护最优的场地生产,最终制剂与包装放在中国,而质量监督仍锚定于一个统一体系。同一方案还附带了配套措施:扩大生物技术、外商独资医院开放试点区域范围,支持保险公司将更多创新药械纳入商业保险,并便利外资企业生产的药品进入零售药店渠道。

外资MAH的操作步骤

  1. 梳理产品组合。 识别符合分段生产条件的分子——生产工艺或设施有特殊要求的创新药、临床急需产品或应急/储备候选品。
  2. 确定中国锚点。 选择哪个生产步骤在中国、由哪家合格生产商执行,以及MAH质量受权职能设在何处。
  3. 设计统一质量体系。 起草覆盖全部场地与分段的单一质量保证框架,包括技术转移、变更控制、偏差处理与CAPA程序。
  4. 尽早与国家药监局沟通。 由于化学药品跨境分段生产实施细则仍在起草中,在投入投资前应利用预沟通渠道对齐预期。
  5. 审查供应链经济性。 建模中间体跨境流动的税收、海关与物流处理,在可行时考虑保税与免税选项。
  6. 协同保险与零售准入。 规划产品如何触达患者——商业保险覆盖与零售渠道进入都影响市场准入规划。

风险与合规提示

分段生产是许可,不是放松。MAH单一责任规则意味着任何分段的失败最终都是MAH的失败;合同生产商的体系必须可审计、可对齐。外资MAH还应跟踪仍在制定的化学药品跨境分段生产实施细则——在细则出台前,小分子药物跨境安排应保守设计。跨境工艺know-how的知识产权保护、场地间GMP一致性、批次放行责任都需要合同上的精确性。最后,药监局现场检查与上市后监管权限不变,因此文档与可追溯性必须满足与单一场地生产相同的标准。

Sources

  • 商务部 国家发展改革委 财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号)——第三条”支持外资参与医药等产业高质量发展”(研究出台药品分段生产实施细则、便利境外MAH跨境分段生产):https://sxdofcom.shaanxi.gov.cn/fdi/yhzc/40265.jhtml
  • 商务部副部长凌激出席国新办发布会介绍利用外资固稳促优有关政策措施(王亚回应医药开放措施,生物制品分段生产试点、化学药品跨境分段生产细则):https://swj.wulanchabu.gov.cn/zxft/1994919.html
  • 中国医药创新促进会《药品管理法实施条例大家谈 在鼓励创新与严守底线间找到平衡》(第三十二条分段生产、MAH统一质量保证体系解读):https://www.phirda.com/artilce_43447.html
  • 山西省民营经济发展局官网《外资企业可重点关注哪些扩大准入领域?》(2026-08-10,摘自商资发〔2026〕97号:药品分段生产、生物技术和外商独资医院领域扩大开放):https://myj.shanxi.gov.cn/ztzl/bwbd/lywzgw/202608/t20260810_10196322.shtml

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening

  • The “Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector” (NHC, MOFCOM et al., Guowei Yizhengfa [2024] No. 36) permits wholly foreign-owned hospitals in nine provincial regions.
    国家卫生健康委、商务部等四部门《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)允许在9个省市设立外商独资医院。
  • The pilot covers Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan, explicitly excluding TCM institutions and the acquisition of public hospitals.
    试点范围涵盖北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛,明确排除中医类机构与并购公立医院。
  • Eligible hospitals are general, specialised or rehabilitation hospitals at tertiary level; blood-disease, psychiatric, infectious-disease and TCM hospitals are barred, and haematology is excluded from the practice scope.
    符合条件的医院类别为综合医院、专科医院、康复医院且级别为三级;禁止设立血液病、精神病、传染病、中医医院,且诊疗科目不得登记血液内科。
  • Foreign and HK/Macao/Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must make up at least 50% of both management and professional staff.
    可按规定聘用外国及港澳台医师短期执业,但全院管理与卫生专业技术人员的中方(内地)人员占比均不得少于50%。
  • Approval sits with provincial health authorities (setting approval plus a five-year practice licence), with information systems connected to local regulatory platforms and data servers located in China.
    设置审批与执业登记由省级卫生健康行政部门核发(执业许可证有效期5年),信息管理系统须接入属地监管平台,服务器位于境内。
  • The plan folds into a broader “orderly expansion of opening in the medical sector” and offers foreign investors a greenfield route distinct from the previous Sino-foreign joint-venture hospital model.
    该方案属于”医疗领域有序扩大开放”整体部署,为外资提供区别于以往中外合资合作医院模式的新设独资路径。

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening | 外资独资医院试点与社会办医扩大开放

Why this matters now

For foreign healthcare groups, China’s hospital market has long been accessible only through joint ventures or minority stakes under the Sino-foreign cooperative medical-institution framework. The late-2024 pilot to permit wholly foreign-owned hospitals changes that calculus: it creates a greenfield route for international operators to build and control a hospital on the mainland, bringing management models, clinical pathways and technology that complement the public system. The pilot is deliberately scoped — geographic, institutional and clinical guardrails are explicit — so the opportunity is real but bounded.

Market context: demand and the foreign-model case

The nine pilot regions are not arbitrary. They combine high openness, dense clusters of foreign enterprises and expatriates, and mature experience regulating foreign-funded medical institutions — exactly the conditions where demand for international-standard care is strongest. Foreign-invested hospitals are positioned to complement, not compete with, the public system: they target high-end and specialised demand, expatriate and cross-border patients, and technology- and service-model transfer that raises local standards. For provincial authorities, the pilot is also a service-environment upgrade that helps retain foreign talent and investment. The 50% mainland-personnel floor and the data-localisation duty, however, mean a foreign operator must build genuine local capability rather than merely import a brand. Realistic entrants therefore pair an international clinical franchise with a credible本地 workforce, IT and quality-system plan from day one.

The pilot framework

Issued by the National Health Commission, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration (Guowei Yizhengfa [2024] No. 36, 1 November 2024), the plan authorises wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan. TCM-category institutions are excluded, and acquiring public hospitals is not permitted. The nine regions were chosen for high openness, concentrated foreign enterprises and expatriates, and mature experience in regulating foreign-funded medical institutions.

Eligibility and operating conditions

The investor must be a legal person able to bear civil liability independently, with direct or indirect experience in healthcare investment and management, and must demonstrate international-leading management, models and equipment that supplement local supply. The hospital itself:

  • may be for-profit or non-profit;
  • must be a general, specialised or rehabilitation hospital at tertiary level — psychiatric, infectious-disease, blood-disease and TCM hospitals are prohibited;
  • may not register haematology as a practice department; and
  • may not conduct high-ethical-risk activities such as organ transplantation, assisted reproductive technology, prenatal screening/diagnosis, psychiatric inpatient care, or experimental cellular tumour therapies.

Foreign, HK/Macao and Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must constitute at least 50% of both the management and the professional workforce. Information systems must connect to the local medical-service supervision platform, and electronic medical records and device data must be stored on servers located in China. Hospitals meeting medical-insurance rules may apply to join the designated insurance network and are encouraged to connect with domestic and international commercial health insurance.

Approval and supervision

Setting approval and practice registration are handled at the prefecture level for initial review and then by the provincial health authority, which issues the certificate of hospital establishment and the practice licence (valid five years, renewable). The licence is brought into the medical-quality safety-management system; hospitals are encouraged to participate in accreditation, and provincial and prefecture authorities conduct ongoing monitoring and coordinated supervision. Importantly, where the pilot conflicts with prior rules, the pilot plan prevails — giving it operative priority during the trial period.

Complementary openings across the medical sector

The hospital pilot is one move in a broader, sequenced opening of the healthcare and pharmaceutical sector. Around the same period, China removed or relaxed restrictions on foreign investment in several medical and aged-care sub-sectors, and the negative list has progressively shed items that previously capped foreign-invested enterprises in healthcare. Innovative-drug and medical-device access pathways have also been streamlined, and Greater Bay Area “medtech connexion” arrangements ease cross-boundary use of approved drugs and devices for residents. Read together, these signal a directional intent to let foreign capital and expertise enter where domestic supply is constrained or where international standards add value. Foreign groups should therefore map the hospital route against this wider roadmap — a hospital licence may pair naturally with device, pharma or senior-care ventures that share the same patient and regulatory ecosystem.

Practical steps for foreign investors

  1. Select a pilot region and confirm the hospital typology (general/specialised/rehabilitation, tertiary) against the exclusions.
  2. Prepare the investment and operating case showing international management, technology and capacity complementarity.
  3. Build the mainland workforce plan that satisfies the 50% Chinese personnel threshold across both management and clinical staff.
  4. Architect the IT and data posture — local servers, platform connectivity, and a data-governance stance consistent with China’s data-security and personal-information rules.
  5. Engage the provincial health authority early for the two-step approval, and plan for the five-year licence cycle and renewal.

Related reading

The hospital pilot sits inside a wider opening of the medical and pharmaceutical sector — from innovative-drug and device access to the negative list’s removal of certain restricted sub-sectors. Foreign groups should read the hospital route together with the broader healthcare-market-access roadmap.


外资独资医院试点与社会办医扩大开放

为何当下值得关注

对境外医疗集团而言,中国医院市场长期以来只能通过合资或少数股权路径进入(即中外合资合作医疗机构框架)。2024年底推出的”允许设立外商独资医院”试点改变了这一格局:它为国际运营方提供了一条在内地自主建设并控股医院的绿地路径,用以引入与公立医院体系互补的管理模式、临床路径与技术。该试点边界清晰——地理、机构与临床层面均设有明确护栏——因此机遇真实但有限定。

市场背景:需求与外资模式的逻辑

9个试点地区并非随意选取。它们兼具对外开放程度高、外资企业与外籍人员密集、监管外资医疗机构经验成熟等特征——恰恰是国际水准医疗需求最旺盛的条件。外商独资医院定位于与公立医院体系互补而非竞争:瞄准高端与专科需求、外籍及跨境患者,并以技术与管理模式转移提升本地标准。对省级政府而言,试点也是留住外资人才与投资的营商环境升级。但中方人员不少于50%与数据本地化义务,意味着外资运营方须建设真实的本地能力,而非仅引入品牌。务实的进入者因此从第一天起就将国际临床品牌与可信的本地人才、IT与质量体系计划相配对。

试点框架

由国家卫生健康委、商务部、国家中医药局、国家疾控局联合印发(国卫医政发〔2024〕36号,2024年11月1日),方案授权在北京、天津、上海、南京、苏州、福州、广州、深圳以及海南全岛设立外商独资医院。明确排除中医类机构,且不允许并购公立医院。选取这9个省市,是因为其对外开放程度高、外资企业与外籍人员集中,且积累了丰富的外资医疗机构管理经验。

资质与运营条件

境外投资者须为能够独立承担民事责任的法人,具有直接或间接医疗卫生投资与管理经验,并能提供国际先进的管理理念、模式与服务,以及国际领先的技术与设备,以补充或改善当地医疗服务能力。医院本身须满足:

  • 经营性质可为营利性或非营利性;
  • 类别为综合医院、专科医院、康复医院且级别为三级——禁止设立精神病、传染病、血液病、中医医院;
  • 诊疗科目不得登记血液内科;
  • 不得开展人体器官移植、人类辅助生殖、产前筛查与诊断、精神科住院治疗、肿瘤细胞治疗新技术试验性治疗等伦理风险较高的诊疗活动。

可按规定聘用外国及港澳台医师短期执业,但中方(内地)人员须占全院管理与卫生专业技术人员的均不少于50%。信息管理系统须接入属地医疗服务监管平台,电子病历与医用设备等信息存储服务器须位于中国境内。符合医保规定的医院可按程序申请纳入医保定点,并鼓励对接国内外商业健康保险。

审批与监管

设置审批与执业登记由地市级卫生健康行政部门初审、省级卫生健康行政部门核发设置医疗机构批准书与医疗机构执业许可证(有效期5年,期满可续)。医院纳入医疗质量安全管理范畴,鼓励参加医院评审评价,省级与地市级部门开展动态监测与协同监管。值得注意的是,原有规定与本试点方案不符的,以本方案为准——在试点期内具有操作优先性。

医疗行业更广维度的配套开放

医院试点只是医疗与医药行业有序、分批扩大开放中的一步。同一时期,中国在多个医疗与养老子行业取消或放宽了外资准入限制,负面清单也逐步删除了此前约束医疗卫生领域外商投资企业的条目。创新药与医疗器械准入路径同步简化,粤港澳大湾区”港澳药械通”等安排也便利了居民跨境使用已获批药品与器械。综合来看,这些举措释放出允许外资与专长进入供给受限或国际标准的确能增值领域的导向性意图。外资集团因此应将医院路径置于更宏观的路线图中研判——一张医院牌照可能天然与共享同一患者与监管生态的器械、药品或养老业务协同。

外资投资者实务步骤

  1. 选定试点地区,并对照排除项确认医院类型(综合/专科/康复,三级)。
  2. 准备投资与运营方案,论证国际管理、技术与能力互补性。
  3. 构建内地人才计划,满足管理与临床中方人员均不少于50%的要求。
  4. 设计IT与数据架构——境内服务器、平台对接,以及与数据安全、个人信息保护规则一致的数据治理立场。
  5. 尽早对接省级卫生健康行政部门完成两步审批,并规划5年证照周期与续期。

延伸阅读

医院试点位于医疗与医药行业更广开放版图之中——从创新药与医疗器械准入,到负面清单取消若干受限子行业。外资集团应将医院路径与更宏观的医疗服务市场准入路线图一并研读。

Sources

  • 国家卫生健康委、商务部、国家中医药局、国家疾控局:《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)— https://www.gov.cn/zhengce/zhengceku/202411/content_6990279.htm

Foreign-invested hospitals: the 2026 liberalisation and where they can land

  • Wholly-foreign-owned hospitals are piloted in nine regions — Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island — under the Nov-2024 pilot plan; outside those areas foreign-invested hospitals remain equity or cooperative joint ventures.
    外商独资医院在九地试点——北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛——依 2024 年 11 月试点方案;试点外外资办医仍以合资/合作形式为主。
  • China’s first wholly-foreign-owned tertiary general hospital — Tianjin Pengruili Hospital — opened on 26 February 2025 with about ¥1 billion invested and 500 beds, after Tianjin issued the first such licence on 16 December 2024.
    中国首家外商独资三级综合医院天津鹏瑞利医院于 2025 年 2 月 26 日开诊,投资约 10 亿元、设 500 张床位;天津于 2024 年 12 月 16 日颁发首张该类执业许可证。
  • The 2026 action plan commits to further expanding the biotech and wholly-foreign-owned-hospital pilot regions after evaluating the initial rollout, signalling that more cities will be added.
    2026 年行动方案承诺在评估初期落地情况后进一步扩大生物技术及外商独资医院试点区域,预示更多城市将加入。
  • The Jan-2026 “nine-city services-opening” comprehensive pilot assigned 159 tasks (103 common plus 3 added) spanning medical-senior-care opening, telecom and finance — extending the policy floor beyond the nine hospital-pilot regions.
    2026 年 1 月”9 城市服务业扩大开放”综合试点部署 159 项任务(103 项共性加 3 项新增),覆盖医疗康养开放、电信、金融等,将政策底盘扩展至九个医院试点区域之外。
  • As of end-2025 a batch of wholly-foreign-owned hospitals had been approved, joining the 60-plus foreign-invested (mostly joint-venture) medical institutions already operating in China.
    截至 2025 年底,一批外商独资医院已获批,叠加中国已有的 60 余家外资(多为合资)医疗机构。
  • Practical constraints are real for foreign investors: TCM is excluded, public-hospital mergers are barred, and human-genetic-resource and data-export rules still apply — so JV and greenfield WFOE each carry trade-offs.
    外资办医仍有实质约束:不含中医类、不含并购公立医院,且人类遗传资源与数据出境规则仍适用——故合资或绿地独资各有权衡。

Foreign-invested hospitals: the 2026 liberalisation and where they can land | 2026 外资办医政策松绑与落地城市

Overview

Healthcare services are among the last major service sectors where foreign access remains conditional in China, but 2024–2026 has brought the most significant opening in a generation. The centrepiece is a pilot that, for the first time, permits wholly-foreign-owned hospitals in nine designated regions, alongside a long-standing joint-venture route that remains available nationwide. The 2026 “Stabilising and Improving Foreign Investment” action plan then commits to widening the pilot further.

This article traces the liberalisation timeline, the nine pilot regions and why they were chosen, the landing cases already on the ground, the joint-venture baseline, and the practical constraints and steps a foreign investor should plan around. It is informational guidance, not regulatory or legal advice.

The liberalisation timeline (2024–2026)

  • September 2024 — three-ministry medical pilot notice. The Ministry of Commerce, the National Health Commission (NHC) and the NMPA issued a notice opening pilot measures in healthcare. In biotech, foreign-invested enterprises were allowed, in the Beijing, Shanghai and Guangdong free-trade zones and the Hainan Free Trade Port, to conduct human stem-cell, gene-diagnosis and gene-therapy technology development and application for product registration and production. In the hospital field, the notice proposed allowing wholly-foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island (TCM excluded; no merger of public hospitals).
  • 1 November 2024 — negative list clears manufacturing. The 2024 negative list took effect, removing the last manufacturing-sector foreign-access restrictions. While hospitals are a service sector, this signalled the broader opening direction and eased ancillary manufacturing (e.g. devices, supplies) for foreign healthcare investors.
  • November 2024 — the WFOE-hospital pilot plan. The NHC, MOFCOM, the National Administration of Traditional Chinese Medicine and the China CDC published the *Pilot Work Plan for Expanding Opening in the Wholly-Foreign-Owned Hospital Field*, formalising the nine-region pilot and the exclusions.
  • January 2026 — nine-city services-opening pilot. MOFCOM issued the comprehensive services-opening pilot tasks for nine cities (led by Dalian), assigning 159 tasks — 103 common tasks plus 3 added — covering medical-senior-care opening, telecom, finance and more, broadening the policy floor well beyond the nine hospital-pilot regions.
  • June 2026 — action plan expansion signal. The State Council information office briefing on the “Stabilising and Improving Foreign Investment” action plan confirmed the biotech pilot covers the Beijing, Shanghai and Guangdong FTZs plus Hainan, and the wholly-foreign-owned-hospital pilot covers the nine regions; it committed to studying a further expansion of these pilot geographies after evaluating the initial rollout.

The nine pilot regions and why

The nine are Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island. The NHC’s stated rationale is practical. First, demand: these are high-openness, foreign-enterprise- and expatriate-dense locations with stronger multi-tiered healthcare demand. Second, governance maturity: since the 2000 *Interim Measures for Sino-Foreign Equity/Cooperative Medical Institutions*, a sizable share of Sino-foreign medical institutions have clustered in exactly these provinces, building regulatory experience. Third, investment weight: these regions account for over 45% of actual utilised foreign capital, making them natural magnets for hospital investment.

Landing cases already on the ground

  • Tianjin Pengruili Hospital — the flagship. On 16 December 2024 Tianjin issued the first wholly-foreign-owned tertiary general hospital licence; the hospital opened on 26 February 2025. Invested by Singapore’s Pengruili (Perennial) Group at about ¥1 billion with 500 beds, it offers broad specialties plus an international department for customised and chronic-disease management, and sits inside the Tianjin South Station health-city TOD complex.
  • Guangzhou — rehab and a tertiary general plan. A Guangzhou development zone partnership with Pengruili is building the city’s first wholly-foreign-owned specialty hospital (a rehabilitation hospital) expected to open by end-2026; a separate Baiyun district project (Phase-I ¥1 billion) is planned as South China’s first wholly-foreign-owned tertiary general hospital.
  • Hainan — timed to the FTP seal. On the day of the Hainan Free Trade Port’s “sealing” at end-2025, a Pengruili-invested wholly-foreign-owned rehabilitation hospital was established there.
  • Scale of the base. As of end-2025, a batch of wholly-foreign-owned hospitals had been approved, joining the 60-plus foreign-invested medical institutions (mostly joint ventures) already operating across China.

The joint-venture baseline (still nationwide)

Wholly-foreign-owned hospitals are a pilot privilege confined to nine regions. Outside them, foreign healthcare investment continues under the 2000 *Interim Measures*, which permit Sino-foreign equity or cooperative medical institutions subject to provincial/municipal health-commission approval. This JV route remains the workhorse for foreign groups that want a China footprint outside the pilot geographies, or that prefer a local partner for land, staffing and payer relationships. Many of the 60-plus existing foreign medical institutions are JVs, and they provide a proven template: foreign capital plus a Chinese partner navigating licensing, staffing and hospital-administration rules.

Practical constraints foreign investors must respect

The opening is real but bounded. Key guardrails:

  • TCM excluded. Wholly-foreign-owned hospitals may not be traditional Chinese-medicine institutions.
  • No public-hospital M&A. The pilot explicitly bars acquiring or merging public hospitals.
  • Human genetic resources. Hospitals engaging in research involving human genetic resources remain subject to HGR approval and compliance — a live constraint for internationally linked groups running trials or biobanks.
  • Data export and cybersecurity. Cross-border transfer of patient or research data must satisfy PIPL and cybersecurity/important-data rules; groups with regional or global data lakes need a compliant architecture.
  • Licensing and staffing. A 医疗机构执业许可证 from the competent health commission is mandatory, and foreign-trained physicians must meet PRC practice-qualification requirements.

What foreign investors should do next

  • Pick the structure by geography. Use the WFOE route only inside the nine pilot regions; elsewhere plan a JV under the 2000 measures.
  • Secure the licence early. Engage the provincial/municipal health commission on the 医疗机构执业许可证 pathway and timeline before committing capital.
  • Choose the city deliberately. Weight the nine pilot regions by expatriate demand, existing foreign-medical-institution experience, and real-estate/payer access; TOD health-city models (as Pengruili deployed) can de-risk fixed costs.
  • Model the exclusions. Confirm the project is neither TCM nor a public-hospital acquisition, and build HGR and data-export compliance into the design from day one.
  • Watch the 2026 expansion. Track the action plan’s further pilot-region enlargement — new eligible cities may open greenfield options without a JV.
  • Plan the JV alternative. Where speed or a local partner matters, the nationwide JV route remains available and battle-tested.

Common pitfalls

  • Assuming WFOE is allowed nationwide. It is confined to the nine pilot regions; elsewhere a JV is required.
  • Assuming TCM or public-hospital M&A is permitted. Both are explicitly excluded from the pilot.
  • Overlooking HGR and data-export rules. International groups running research or centralising data can breach HGR/PIPL without a compliant design.
  • Underestimating licensing and staffing lead times. The 执业许可证 and physician-qualification pathway are the critical path, not the capital.
  • Treating the pilot as settled national policy. It remains a pilot whose geography and conditions can expand or adjust — plan for change.

Sources

  • 国务院新闻办发布会介绍利用外资固稳促优有关政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 人民日报(海外版)《独资医院领域扩大开放试点工作方案》解读 (2024-12-03): https://paper.people.com.cn/rmrbhwb/pc/content/202412/03/content_30032517.html
  • 光明日报《我国首家外商独资三级综合医院开诊》(2025-02-27): https://m.gmw.cn/gmsogh/202502/27/37873333.html
  • 商务部(MOFCOM)官方门户:https://www.mofcom.gov.cn

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 外资办医政策松绑与落地城市

概述

医疗服务是中国少数外资准入仍属有条件开放的服务大类中之一,但 2024–2026 年迎来了 Generation 以来最显著的开放。核心是一项和以往不同、首次允许在九个指定区域设立外商独资医院的试点,同时全国仍可走的合资路线依旧有效。2026 年《利用外资固稳促优行动方案》进而承诺进一步扩大试点。

本文梳理开放时间线、九个试点区域及其选定逻辑、已落地的案例、合资基线,以及外资投资者须规划的实务约束与步骤。本文仅为信息参考,不构成监管或法律意见。

开放时间线(2024–2026)

  • 2024 年 9 月——三部委会医疗试点通知。 商务部、国家卫健委、国家药监局印发在医疗领域开展扩大开放试点的通知。生物技术领域,允许外商投资企业在北京、上海、广东自由贸易试验区与海南自由贸易港,从事人体干细胞、基因诊断与治疗技术开发和应用,用于产品注册上市和生产。医院领域,拟允许在北京、天津、上海、南京、苏州、福州、广州、深圳、海南全岛设立外商独资医院(中医类除外,不含并购公立医院)。
  • 2024 年 11 月 1 日——负面清单清空制造业。 2024 年版负面清单施行,清除制造业领域最后的外资准入限制。医院虽属服务业,但此举表明整体开放方向,并便利了外资医疗投资者的配套制造(如器械、耗材)。
  • 2024 年 11 月——独资医院试点方案。 国家卫健委、商务部、国家中医药局、国家疾控局公布《独资医院领域扩大开放试点工作方案》,固化九区域试点与除外情形。
  • 2026 年 1 月——九城市服务业扩大开放试点。 商务部印发大连等 9 城市服务业扩大开放综合试点任务,部署 159 项(103 项共性加 3 项新增),覆盖医疗康养开放、电信、金融等,将政策底盘大幅扩展至九个医院试点区域之外。
  • 2026 年 6 月——行动方案扩围信号。 国务院新闻办在《利用外资固稳促优行动方案》发布会上确认:生物技术试点覆盖北京、上海、广东 3 个自贸区加海南,外商独资医院试点覆盖九地;并承诺在评估初期落地后,抓紧研究进一步扩大上述领域试点地域范围。

九个试点区域及其逻辑

九地为北京、天津、上海、南京、苏州、福州、广州、深圳与海南全岛。国家卫健委给出的理由务实。其一,需求:这些地区开放度高、外资企业与外籍人员密集,多元化医疗需求更强。其二,治理成熟度:自 2000 年《中外合资、合作医疗机构管理暂行办法》以来,相当比例的中外医疗机构正聚集于这九省市,积累了监管经验。其三,投资权重:这些区域实际使用外资总额占比超 45%,天然是医院投资磁石。

已落地案例

  • 天津鹏瑞利医院——旗舰。 2024 年 12 月 16 日天津颁发首张外商独资三级综合医院执业许可证;医院于 2025 年 2 月 26 日开诊。由新加坡鹏瑞利集团投资约 10 亿元、设 500 张床位,提供多专科及面向定制与慢病管理的国际部,坐落于天津南站健康城 TOD 综合体。
  • 广州——康复与三级综合布局。 广州开发区与鹏瑞利合作建设全市首家外商独资专科医院(康复医院),预计 2026 年底运营;白云区另有一期投资 10 亿元的项目,规划为华南首家外商独资三级综合医院。
  • 海南——卡位封关。 2025 年底海南自由贸易港封关当日,鹏瑞利投资的外商独资康复医院同步落户。
  • 存量规模。 截至 2025 年底,一批外商独资医院已获批,叠加中国已有的 60 余家外资(多为合资)医疗机构。

合资基线(仍全国可用)

外商独资医院是限于九区域的试点特权。在其之外,外资办医仍依 2000 年《暂行办法》以中外合资或合作医疗机构形式,经省级/市级卫健部门批准设立。这条合资路线仍是想在中国落子、但位于试点区域之外,或偏好本地伙伴以处理土地、人员与支付关系的集团的主力选择。现有的 60 余家外资医疗机构多为合资,提供了成熟模板:外资加中国伙伴共同应对许可、人员与医院管理规则。

外资投资者须遵守的实务约束

开放真实但有边界。关键护栏:

  • 不含中医类。 外商独资医院不得为中医类机构。
  • 不含并购公立医院。 试点明确禁止并购或合并公立医院。
  • 人类遗传资源。 涉及人类遗传资源的研究仍须 HGR 审批与合规——对开展试验或生物样本库的国际化集团是实约束。
  • 数据出境与网络安全。 患者或研究数据的跨境传输须满足《个人信息保护法》及网络安全/重要数据规则;拥有区域或全球数据湖的集团需合规架构。
  • 许可与人员。 须取得卫健部门颁发的《医疗机构执业许可证》;境外 trained 医师须满足中国执业资格要求。

外资投资者下一步

  • 按地域选结构。 独资路线仅限九个试点区域内使用;区域外须按 2000 年办法走合资。
  • 尽早取证。 在投入资本前,就《医疗机构执业许可证》路径与时间表对接省级/市级卫健部门。
  • 审慎择城。 在九试点区域中按外籍需求、既有外资医疗经验、地产与支付可及性加权;TOD 健康城模式(如鹏瑞利)可摊薄固定成本。
  • 建模除外项。 确认项目既非中医类也非公立医院并购,并将 HGR 与数据出境合规从第一天纳入设计。
  • 跟踪 2026 年扩围。 关注行动方案进一步扩大的试点区域——新合格城市可能无需合资即开放绿地选项。
  • 规划合资备选。 当速度或本地伙伴重要时,全国可用的合资路线仍稳健可靠。

常见误读

  • 以为独资全国放开。 其限于九个试点区域;区域外须为合资。
  • 以为中医类或并购公立医院可行。 两者均被试点明确排除。
  • 忽视 HGR 与数据出境规��。 开展研究或集中数据的国际集团,若无合规设计易触 HGR/PIPL 红线。
  • 低估许可与人员周期。 执业许可证与医师资格路径才是关键路径,而非资本。
  • 把试点当既定国策。 其仍是试点,地域与条件可能扩围或调整——须为变化留预案。

来源

  • 国务院新闻办发布会介绍利用外资固稳促优有关政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 人民日报(海外版)《独资医院领域扩大开放试点工作方案》解读(2024-12-03):https://paper.people.com.cn/rmrbhwb/pc/content/202412/03/content_30032517.html
  • 光明日报《我国首家外商独资三级综合医院开诊》(2025-02-27):https://m.gmw.cn/gmsogh/202502/27/37873333.html
  • 商务部(MOFCOM)官方门户:https://www.mofcom.gov.cn

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan

Visa Facilitation for Business Visitors to China in 2026: Transit, Unilateral and Port-Visa Options Compared

  • China now offers business visitors three layered, non-exclusive entry conveniences — 240-hour transit visa-free, unilateral visa-free for 50 countries, and port visa / APEC Business Travel Card — and choosing the right one depends on itinerary, nationality and purpose.
    中国目前为商务访客提供三层叠加、互不排斥的入境便利——240小时过境免签、对50国的单方面免签,以及口岸签证与APEC商务旅行卡;正确选择取决于行程、国籍与目的。
  • The 240-hour (10-day) transit visa-free scheme covers 55 countries, 65 open ports across 24 provinces, and permits tourism, business, visits and family reunions during the stay.
    240小时(10天)过境免签覆盖55个国家、24个省份的65个开放口岸,停留期间可从事旅游、商务、访问与探亲活动。
  • As of 17 February 2026, China applies unilateral visa-free entry to 50 countries for stays up to 30 days for business, tourism, family visits, exchanges and transit.
    截至2026年2月17日,中国对50个国家实施单边免签,因经商、旅游观光、探亲访友、交流访问、过境事由来华可免签停留不超过30日。
  • Regional entry visa-free schemes — Hainan (59 countries, 30 days), cruise tours, ASEAN tour groups and HK/Macau-organsied foreign tour groups into the Greater Bay Area or Hainan — open targeted corridors for business-and-leisure combinations.
    区域性入境免签——海南(59国、30天)、邮轮免签、东盟旅游团免签,以及经港澳旅行社组团免签进入大湾区或海南——为”商务+休闲”组合打开了定向通道。
  • Port visas let qualifying foreign business visitors obtain a visa on arrival at designated ports when an invitation letter and supporting documents are ready, and the APEC card enables multi-year, multi-economy transit.
    口岸签证允许符合条件的外国商务人员凭邀请函等证明材料在指定口岸落地办证,APEC商务旅行卡则实现多年期、多经济体的通行。
  • None of these substitutes for a work or study visa; paid employment, study and news reporting still require prior approval, and overstayers face fines, detention and future-entry bans.
    上述任何一项都不能替代工作或学习签证;有偿就业、留学与新闻采访仍须事先批准,逾期停留将面临罚款、拘留与未来入境限制。

Visa Facilitation for Business Visitors to China in 2026: Transit, Unilateral and Port-Visa Options Compared | 2026年外国商务人员来华免签与口岸签证便利:过境免签、单方面免签与口岸签证对照

Why this matters now

Easing the movement of people is now a stated tool of investment promotion. The *Action Plan for Stabilising and Optimising Foreign Investment* (MOFCOM, NDRC and MOF, Document No. 97 of 2026) explicitly lists transit visa-free, tax-refund-on-departure and cross-border payment measures among the ways China optimises the internationalised business environment. For the foreign executive weighing a week of client meetings, a factory inspection or a board session in China, the visa question is often the first friction point. The good news: the default answer is increasingly “you may not need a visa at all,” provided the itinerary fits one of three layered schemes.

This article compares the 240-hour transit visa-free programme, the unilateral visa-free list, the regional entry schemes and the port-visa / APEC options, and gives a practical decision checklist. It complements — but does not duplicate — our companion pieces on work visas and the APEC Business Travel Card.

The 240-hour transit visa-free programme

The flagship convenience is the 240-hour (10-day) transit visa-free policy. A national of one of 55 designated countries, holding a valid international travel document and a connecting ticket with a confirmed date and seat to a third country or region, may enter visa-free through any of 65 open ports in 24 provinces and stay up to 10 days. During the stay, permitted activities include tourism, business, visiting and family reunion. Paid work, study and news reporting still require prior approval.

The scheme has been upgraded repeatedly: from 72 hours (2013), to 144 hours, to 240 hours, with the country list growing to 55 and ports to 65 by late 2025. For a business visitor transiting through China en route to a third country — say, Tokyo → Shanghai → Frankfurt — the 240-hour window is usually ample for meetings without any visa application.

Unilateral visa-free for 50 countries

Beyond transit, China applies a unilateral visa-free policy to 50 countries (as published by the National Immigration Administration on 17 February 2026). Nationals of these countries, travelling on an ordinary passport for business, tourism, family visits, exchanges or transit of no more than 30 days, may enter visa-free. The list spans Europe (35 countries, including France, Germany, Italy, the UK, Russia and the Nordics), Oceania (Australia, New Zealand), Asia (Japan, South Korea, Saudi Arabia, the Gulf states) and the Americas (Brazil, Argentina, Chile, Peru, Uruguay, Canada).

This is the single most useful instrument for short business development trips: a German or Brazilian executive can fly in, attend meetings, sign a term sheet and leave within 30 days with no consular step. It is unilateral — China grants it without reciprocity — and can be adjusted, so travellers should confirm the current list before booking.

Regional entry visa-free schemes

A family of *regional* schemes opens targeted corridors, useful when the trip blends business with leisure or centres on a specific zone:

  • Hainan: nationals of 59 countries may enter visa-free and stay up to 30 days.
  • Cruise tours: foreign tour groups of two or more may enter visa-free through 13 cruise ports along coastal provinces and Beijing, staying up to 15 days.
  • ASEAN tour groups: ASEAN nationals may enter visa-free as tour groups into Xishuangbanna (Yunnan) or Guilin (Guangxi), up to 6 days.
  • HK/Macau-organised foreign tour groups: foreign groups organised by HK or Macau travel agencies may enter the nine mainland cities of the Greater Bay Area plus Shantou, or Hainan, visa-free for up to 6 days.

For an investor combining site visits in the Greater Bay Area with a short holiday, the HK/Macau-group route is a practical, low-friction option.

Port visa and APEC Business Travel Card

When a trip does not fit the above — for example, a last-minute technical assignment, or a nationality outside the eligible lists — a port visa remains available. Qualifying foreign business visitors may, with an invitation letter from a domestic entity and supporting documents, apply for a visa on arrival at designated ports. Processing is fast and designed for genuine, time-sensitive commercial need.

The APEC Business Travel Card offers a multi-year, multi-economy shortcut for senior executives from APEC economies: it functions as a multiple-entry visa and enables expedited immigration lanes across member economies, materially cutting the administrative load of repeated travel. We cover it in detail separately.

Practical decision checklist

  1. Transiting to a third country? Use 240-hour transit visa-free (55 countries, 65 ports, 24 provinces).
  2. From one of the 50 unilateral countries, stay ≤30 days, no work/study? Enter visa-free directly.
  3. Trip centres on Hainan / a cruise / an ASEAN or HK-Macau group? Use the matching regional scheme.
  4. Eligible APEC economy executive with frequent travel? Hold an APEC card.
  5. None of the above, or paid work / study / reporting? Obtain the correct visa (port visa for urgent business; work/residence permit for employment).
  6. Always: confirm the current eligible-country list and port list before ticketing, carry the onward ticket, and never overstay.

Related reading

  • Work visas and residence permits for foreign employees in China.
  • The APEC Business Travel Card and port-visa routes for business travellers.
  • Regional visa-free entry schemes and the Greater Bay Area mobility picture.

2026年外国商务人员来华免签与口岸签证便利:过境免签、单方面免签与口岸签证对照

为何重要

便利人员往来已成为引资促商的一项明确工具。《利用外资固稳促优行动方案》(商务部、国家发展改革委、财政部,2026年第97号)明确将过境免签、离境退税与涉外支付等措施列为优化国际化营商环境的具体抓手。对于正盘算一周客户拜访、工厂巡查或董事会行程的外国高管而言,签证往往是第一道摩擦点。好消息是:只要行程契合三层便利方案之一,答案越来越可能是”你根本不需要签证”。

本文对比240小时过境免签、单方面免签清单、区域性入境免签,以及口岸签证与APEC选项,并给出实用的决策清单。它与本站点关于工作签证、APEC商务旅行卡的专文互为补充,但不重复。

240小时过境免签方案

最具标志性的便利是240小时(10天)过境免签。55个指定国家的公民,持有效国际旅行证件和前往第三国(地区)且日期、座位已确定的联程客票,可从24个省份的65个开放口岸免签入境,停留不超过10天。停留期间可从事旅游、商务、访问、探亲等活动;有偿工作、留学与新闻采访仍须事先批准。

该方案历经多次升级:从2013年的72小时,到144小时,再到240小时,适用国家增至55个、口岸增至65个(2025年底)。对于经中国中转前往第三国的商务访客——例如东京→上海→法兰克福——240小时窗口通常足以完成会议而无需任何签证申请。

对50国的单方面免签

在过境之外,中国对50个国家实施单方面免签(国家移民管理局2026年2月17日公布)。这些国家公民持普通护照,因经商、旅游观光、探亲访友、交流访问、过境事由来华、停留不超过30日的,可免签入境。清单覆盖欧洲(35国,含法国、德国、意大利、英国、俄罗斯及北欧国家)、大洋洲(澳大利亚、新西兰)、亚洲(日本、韩国、沙特及海湾国家)与美洲(巴西、阿根廷、智利、秘鲁、乌拉圭、加拿大)。

这是短期商务拓展行程最实用的工具:德国或巴西高管可以飞抵、参会、签署条款清单并在30天内离境,无需任何领事步骤。该政策是单边的(中国单方面给予、不要求对等),并可能调整,出行人应在订票前确认最新清单。

区域性入境免签方案

一族*区域性*方案打开了定向通道,适用于”商务+休闲”结合或围绕特定区域的行程:

  • 海南: 59国公民可免签入境,停留不超过30天。
  • 邮轮免签: 2人及以上外国旅游团可经13个邮轮口岸及北京市免签入境沿海省(区、市),停留不超过15天。
  • 东盟旅游团: 东盟国家旅游团可分别免签入境云南西双版纳或广西桂林,停留不超过6天。
  • 港澳组团: 经港澳旅行社组团的外国旅游团,可免签进入大湾区内地9市及汕头,或免签入境海南,停留不超过6天。

对于将大湾区实地考察与短途休假结合的投资者,港澳组团路线是务实、低摩擦的选择。

口岸签证与APEC商务旅行卡

当行程不符合上述情形——例如临时的技术派驻,或国籍不在适用清单内——口岸签证仍是可行路径。符合条件的外国商务人员,凭国内单位邀请函及证明材料,可在指定口岸落地申请签证。办理快捷,专为真实、时效敏感的商务需求设计。

APEC商务旅行卡为APEC经济体高管提供多年期、多经济体的通行捷径:兼具多次入境签证功能,并在成员经济体间启用快速通道,显著降低频繁出行的行政负担。本站点另有专文详述。

实用决策清单

  1. 经第三国中转? 用240小时过境免签(55国、65口岸、24省)。
  2. 来自50个单方面免签国、停留≤30天、无工作/留学? 直接免签入境。
  3. 行程围绕海南/邮轮/东盟或港澳组团? 用对应的区域性方案。
  4. 属APEC经济体、频繁出行的高管? 持有APEC卡。
  5. 以上均不符合,或有偿工作/留学/采访? 办理相应签证(紧急商务走口岸签证;就业办工作居留许可)。
  6. 始终: 订票前确认最新适用国家与口岸清单,携带后续行程客票,切勿逾期。

延伸阅读

  • 外籍员工在华的工作签证与居留许可。
  • APEC商务旅行卡与面向商务人员的口岸签证路径。
  • 区域性入境免签方案与大湾区的人员流动图景。

Sources

  • 国家移民管理局:单方面免签国家名单(2026年2月17日)— https://nia.gov.cn/n741440/n741577/c1731154/content.html
  • 国家移民管理局:中国240小时过境免签政策(在线咨询答复,含55国/65口岸)— https://www.nia.gov.cn/Enquiry/publish/preShowQuestion.jsp
  • 国家移民管理局官网(签证政策与出入境管理专栏)— https://www.nia.gov.cn

China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026)

  • China now grants unilateral visa-free entry to ordinary passport holders of 50 countries, valid nationwide for stays up to 30 days.
    中国目前对 50 个国家的普通护照持有人实施单方面免签,可在全国范围停留不超过 30 天。
  • The policy was extended on 3 November 2025 to 31 December 2026, and Sweden was added as the latest European entrant from 10 November 2025.
    该政策于 2025 年 11 月 3 日延期至 2026 年 12 月 31 日,并自 2025 年 11 月 10 日起将瑞典纳入免签范围。
  • No visa, no connecting ticket, and no pre-arranged invitation are required — but paid employment is strictly prohibited under the waiver.
    免签入境无需签证、无需联程客票、也无需预先邀请函,但严禁以该政策从事有偿工作。
  • The 30-day clock starts on the calendar day after entry, and overstayers must apply for a stay permit rather than a simple extension.
    30 天停留期自入境次日零时起算,超期者须申请停留证件而非简单续签。
  • Unilateral visa-free entry is nationwide and individual-based, unlike the 240-hour transit waiver (third-country onward ticket, limited ports) and regional entry waivers (Hainan, cruise, ASEAN groups).
    单方面免签面向个人、全国通行,与 240 小时过境免签(需赴第三国联程票、限定口岸)及区域性入境免签(海南、邮轮、东盟旅游团)明显不同。
  • Foreign business travellers can use it for short trips — meetings, site visits, trade fairs, and partner exchanges — without a formal work visa, as long as they do not take up local employment.
    外籍商务人士可用它开展短期差旅——会议、实地考察、参展、伙伴交流——无需正式工作签证,前提是不在当地受雇务工。

China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026) | 中国单方面免签政策:外籍商务差旅实操指引(2026)

Overview

Since late 2023, China has rolled out one of the most significant liberalisations of its short-stay entry regime in decades: a unilateral visa waiver under which ordinary passport holders of a growing list of countries may enter China without a visa for business, tourism, family visits, exchange, or transit, for stays of no more than 30 days. Unlike reciprocal treaties, this waiver is granted by China alone.

By March 2026, Foreign Minister Wang Yi confirmed unilateral visa-free arrangements for 50 countries and full mutual visa-free agreements with 29 countries, with visa-free entries at 73% of all foreign arrivals. This article focuses on the unilateral stream — its country coverage, the 2024–2026 expansion rhythm, and the practical entry rules.

The waiver is deliberately simple. It removes the single biggest friction point for short visits — obtaining a Chinese visa in advance — and applies nationwide, not just to specific provinces or ports. For foreign-invested enterprises, chambers of commerce, and individual professionals, it has become the default channel for short business trips.

Which countries are covered

The 50-country list is the result of incremental additions between November 2023 and February 2026, grouped by region below (per the February 2026 consular FAQ and the November 2025 extension notice).

RegionCountries (ordinary passport holders)
Europe (32)France, Germany, Italy, Netherlands, Spain, Switzerland, Ireland, Hungary, Austria, Belgium, Luxembourg, Poland, Portugal, Greece, Cyprus, Slovenia, Slovakia, Norway, Finland, Denmark, Iceland, Andorra, Monaco, Liechtenstein, Bulgaria, Romania, Croatia, Montenegro, North Macedonia, Malta, Estonia, Latvia
Asia (7)Brunei, Republic of Korea, Japan, Saudi Arabia, Oman, Kuwait, Bahrain
Oceania (2)Australia, New Zealand
Americas (5)Brazil, Argentina, Chile, Peru, Uruguay
Added later (4)Russia (Sep 2025), Sweden (Nov 2025), Canada (Feb 2026), United Kingdom (Feb 2026)

Validity notes for trip planning:

  • Brunei — open-ended, no expiry set.
  • Russia — per the February 2026 FAQ, currently runs to 31 December 2027.
  • The other 48 countries — extended to 24:00 on 31 December 2026.
  • Sweden — from 10 November 2025 to 31 December 2026.
  • Canada and the United Kingdom — from 17 February 2026 to 31 December 2026.

Because the list has shifted several times, re-confirm against the latest consular notice before booking.

The 2024–2026 expansion and extension timeline

The policy expanded in waves, each later bundled into a single extension. Key milestones:

  • Dec 2023 – Nov 2024: Pilot waiver for France, Germany, Italy, Netherlands, Spain, and Malaysia (15-day stay).
  • Mid-2024: Australia and New Zealand added, then a bloc of Central and Eastern European states and the Republic of Korea.
  • Late 2024: Japan and South American states Brazil, Argentina, Chile, Peru, and Uruguay added.
  • 9 June 2025: Saudi Arabia, Oman, Kuwait, and Bahrain added (initially a one-year trial).
  • 15 September 2025: Russia added.
  • 3 November 2025: The Ministry of Foreign Affairs announced the extension of the 45-country waiver to 31 December 2026 and added Sweden (effective 10 November 2025).
  • 17 February 2026: Canada and the United Kingdom added, also to 31 December 2026.

Frequent, often annual, extensions plus steady additions define the unilateral stream. Policymakers have signalled intent to keep optimising it, so further extensions beyond 2026 are widely expected.

Practical entry rules

The waiver is governed by the consular FAQ and border-inspection practice. The essentials:

  1. No visa required. Eligible nationals present a valid ordinary passport at an open port.
  2. No connecting ticket required. Unlike the transit waiver, no onward ticket to a third country is needed; entry and exit may be from any country or region.
  3. Purpose of stay. Business, tourism, family/friend visits, exchange, and transit are covered, as are study tours, conferences, exhibitions, and sports competitions under 30 days.
  4. No employment. The waiver does not apply to work, study, journalism, or similar purposes. Paid local employment is prohibited; use a proper work or Z-visa pathway.
  5. Passport validity. An ordinary passport valid for at least the intended stay is needed. Travel, temporary, or emergency documents are not accepted.
  6. Any mode and any port. Entry by air, sea, or road through any open port is allowed (private vehicles need ordinary transport-entry formalities).
  7. Stay calculation. The 30 days run from the calendar day after entry (自入境次日起算).
  8. Overstay handling. For proper reasons beyond 30 days, apply for a stay permit (停留证件); a simple visa-free “extension” does not exist.
  9. Supporting documents. Border inspection may verify purpose; carry an invitation letter, bookings, or similar proof. Minors follow the same rules.

For business travellers, a routine market visit, supplier meeting, or trade-fair trip is frictionless within 30 days and without employment.

How it differs from transit and regional waivers

China operates three distinct short-stay entry channels:

  • Unilateral visa-free (this article): nationwide, individual-based, up to 30 days, no onward ticket, no visa. Covers the 50 named countries.
  • 240-hour transit waiver (covered in article 79): confirmed onward ticket to a third country/region, designated ports in 24 provinces, stay within defined areas up to 10 days. Open to ~55 countries.
  • Regional entry waivers (covered in article 173): geographically confined — 30-day Hainan entry for 59 countries, cruise groups through 13 ports, ASEAN groups in Yunnan and Guangxi. Group or area limits apply.

In short: the unilateral waiver is the most flexible for an individual business trip; the transit waiver is for genuine onward travel; the regional waivers are for destination-specific tourism.

What foreign businesses should do

For FDI-related travel, the unilateral waiver lowers the cost of doing business in China. Recommended steps:

  1. Map eligible nationalities. If your headquarters, suppliers, or clients are in the 50 countries, short trips need no visa lead time.
  2. Keep trips under 30 days and non-employment. Use the waiver for meetings, inspections, due diligence, and exhibitions; for assignments or on-site work, use a work or business (M) visa.
  3. Carry purpose evidence. A Chinese invitation letter (邀请函) and bookings smooth border inspection and later stay-permit applications.
  4. Plan around expiry dates. Waivers lapse on 31 December 2026 (Russia to 2027). Watch for the next extension round before year-end trips.
  5. Combine with the transit waiver. Travellers from non-listed countries (e.g., the United States) can still use the 240-hour transit waiver for genuine onward journeys.
  6. Brief relocating staff separately. The waiver is not a route to residency; long-term presence needs the standard work- and residence-permit process.

Related reading

  • 240-hour visa-free transit (article 79) — the onward-ticket, port-limited channel.
  • Regional entry waivers (article 173) — Hainan, cruise, and ASEAN group entry.
  • Ministry of Foreign Affairs consular FAQ and mutual visa-free treaty list for the latest country updates.

中国单方面免签政策:外籍商务差旅实操指引(2026)/ China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026)

概述

自 2023 年底起,中国推出了数十年来力度最大的短期入境便利化举措之一——单方面免签政策:符合清单的国家,其普通护照持有人来华经商、旅游观光、探亲访友、交流访问、过境,停留不超过 30 天的,可免办签证入境。与对等(互免)签证协定不同,这一免签由中国单方给予,伙伴国无须对中国护照持有人给予同等待遇。对企业而言,这意味着总部外派、客户拜访、供应商审核等高频短差,不再被签证周期”卡脖子”,决策与成行之间的时滞大幅压缩。

截至 2026 年 3 月,外交部长王毅确认,中国已对 50 个国家实施单方面免签,并与 29 个国家实现全面互免签证,前一年免签入境的外籍人士占比高达 73%。在稳外资、扩开放的背景下,这条通道对外国投资者意义尤为直接:它把”想来就能来”的门槛降到最低。本文聚焦”单方面免签”这一条线——覆盖国家、2024–2026 年的扩容与延期节奏、入境实操规则,以及它与本站点另文介绍的 240 小时过境免签和区域性入境免签的区别。

单方面免签的设计刻意保持简单:它消除了短期访问最大的摩擦点——提前办理中国签证,而且适用全国,而不限于特定省份或口岸。对外商投资企业、商会以及个人专业人士而言,它已成为短期差旅的默认通道。与互免协定不同,这一便利由中国单方给予,伙伴国无须对中国护照持有人对等开放,因此扩容节奏完全由中国自主决定,这也解释了为何名单能在两年内迅速拉长。值得注意的是,单方面免签与互免协定并行不悖:前者针对 50 国、后者覆盖 29 国,二者共同构成中国”免签朋友圈”的双支柱,外籍人士来华短期停留的便利度因此大幅提升。

覆盖哪些国家

这 50 国名单是 2023 年 11 月至 2026 年 2 月逐步扩容的结果,呈现出”欧洲为主、亚太与美洲跟进、海湾与北美收尾”的清晰轨迹。下表按地区分组(依据 2026 年 2 月领事常见问题解答及 2025 年 11 月延期通知):

地区国家(普通护照持有人)
欧洲(32 国)法国、德国、意大利、荷兰、西班牙、瑞士、爱尔兰、匈牙利、奥地利、比利时、卢森堡、波兰、葡萄牙、希腊、塞浦路斯、斯洛文尼亚、斯洛伐克、挪威、芬兰、丹麦、冰岛、安道尔、摩纳哥、列支敦士登、保加利亚、罗马尼亚、克罗地亚、黑山、北马其顿、马耳他、爱沙尼亚、拉脱维亚
亚洲(7 国)文莱、韩国、日本、沙特、阿曼、科威特、巴林
大洋洲(2 国)澳大利亚、新西兰
美洲(5 国)巴西、阿根廷、智利、秘鲁、乌拉圭
后续新增(4 国)俄罗斯(2025 年 9 月)、瑞典(2025 年 11 月)、加拿大(2026 年 2 月)、英国(2026 年 2 月)

出行规划需注意以下有效期要点:

  • 文莱——未设截止日期,免签长期有效,是清单中唯一无明确到期日的国家。
  • 俄罗斯——试行免签自 2025 年 9 月 15 日至 2026 年 9 月 14 日,但 2025 年 11 月的延期将一般截止日推至 2026 年 12 月 31 日;据 2026 年 2 月领事解答,俄罗斯安排目前施行至 2027 年 12 月 31 日,是有效期最长者。
  • 其余 48 国——免签均延期至 2026 年 12 月 31 日 24 时。
  • 瑞典——自 2025 年 11 月 10 日起覆盖至 2026 年 12 月 31 日,是欧洲名单中的最新成员。
  • 加拿大、英国——自 2026 年 2 月 17 日起覆盖至 2026 年 12 月 31 日,是北美两大经济体加入的标志性节点。

由于名单多次调整,旅行者应在订票前务必对照最新领事通知再次核实,因为各试用期和截止日会随每次延期而变动。建议把”以出发当日官方清单为准”作为内部差旅政策的硬性提醒。

2024–2026 年扩容与延期节奏

该政策并非一次性成型,而是分批扩容,每批随后又被统一延期。关键节点如下:

  • 2023 年 12 月 1 日 – 2024 年 11 月 30 日:对法国、德国、意大利、荷兰、西班牙、马来西亚试行免签(停留 15 天),迈开单方面开放的第一步。
  • 2024 年中:新增澳大利亚、新西兰;随后加入一批中东欧国家(如匈牙利、奥地利、比利时、瑞士、波兰、葡萄牙、希腊等)及韩国,欧洲”朋友圈”迅速铺开。
  • 2024 年底:新增日本,以及南美的巴西、阿根廷、智利、秘鲁、乌拉圭,并加入更多欧洲国家,名单首次突破四十国量级。
  • 2025 年 6 月 9 日:新增沙特、阿曼、科威特、巴林,海湾阿拉伯国家首次整批进入免签清单。
  • 2025 年 9 月 15 日:新增俄罗斯,地缘邻近的大体量客源市场被纳入。
  • 2025 年 11 月 3 日:外交部宣布将 45 国免签延期至 2026 年 12 月 31 日,并新增瑞典(自 2025 年 11 月 10 日起),把北欧主要经济体补齐。
  • 2026 年 2 月 17 日:新增加拿大、英国,传统英语国家两大经济体入场,名单最终达到 50 国。

这种”频繁、往往按年”的延期叠加持续扩员,是单方面免签最鲜明的特征。政策制定者已释放出继续优化的信号,外界普遍预期 2026 年之后还会进一步延期,企业可将其作为中期可依赖的常态通道来规划。

入境实操规则

免签政策由领事常见问题解答及边检实践规范,要点如下:

  1. 无需签证。 符合条件者只需在对外开放口岸出示有效普通护照即可,无需提前向使领馆送签、缴费、等待制证。
  2. 无需联程客票。 与过境免签不同,您不需要赴第三国的联程机票,可从任何国家或地区出入境,往返行程自由安排。
  3. 入境目的。 经商、旅游、探亲访友、交流、过境均涵盖;不超过 30 天的研学、参会、参展、体育竞赛同样适用,覆盖面较广。
  4. 不得就业。 免签不适用于工作、学习、新闻采访等目的。禁止在当地从事有偿工作,须走正规的工作签证(Z 字签证)路径;即便短期项目支持,也建议先确认是否落入”就业”范畴。
  5. 护照有效性。 须持有效期至少覆盖拟停留期的普通护照。旅行证、临时或紧急护照不能用于免签入境。
  6. 任何交通方式、任何口岸。 经航空、海路或陆路从任一对外开放口岸入境均可(私家车入境须按规办理交通工具入出境手续)。
  7. 停留期计算。 30 天自入境次日零时起算,满 30 个自然日;例如 1 日入境,停留期至当月 31 日届满。
  8. 超期处理。 因正当理由需超过 30 天的,应向公安出入境管理部门申请停留证件;不存在”免签直接续期”一说,勿心存侥幸逾期。
  9. 佐证材料。 边检可能核实入境目的。请携带与所申报目的相符的邀请函、机票/酒店预订等证明;未成年人与成年人规则一致。

对商务旅客而言,常规的市场走访、供应商会议、参展等差旅因此变得顺畅——只要停留不超过 30 天且不越界就业,几乎可以”说走就走”。

与过境免签、区域性免签的区别

中国有三条性质不同的短期入境通道,需厘清:

  • 单方面免签(本文):全国通行、面向个人、最长 30 天、无需联程票、无需签证。覆盖前述 50 国,是三者中自由度最高的”个人通道”。
  • 240 小时过境免签(79 号文):须持赴第三国/地区的确定联程客票,从 24 个省份指定口岸入境,在规定区域停留不超过 10 天。面向约 55 国,本质是”中转”便利。
  • 区域性入境免签(173 号文):受地域限制——59 国入境海南 30 天、13 个邮轮口岸的旅游团入境、东盟旅游团赴云南(西双版纳)与广西(桂林)。多有限团或限区要求,属”目的地”便利。

简言之:单方面免签对个人商务差旅最灵活;过境免签适用于真实的中转行程;区域性免签适用于特定目的地旅游。三者各有适用面,企业可按行程性质择优选用。

需要特别提示的是,这三条通道并非互相排斥:同一位旅客完全可能在一次行程中组合使用。例如,一位不在 50 国清单内的美国商务人士,可先以 240 小时过境免签入境参会,若后续还需以个人身份旅游,则可另行规划。理解各自边界,才能把政策红利用足而不越线。

外籍商务人士应如何运用

就外资相关差旅而言,单方面免签显著降低了在华营商成本。建议做法:

  1. 梳理组织内符合资格国籍。 若总部、供应商或客户位于 50 国之中,短期行程无需签证办理周期,可把”免签国公民”标注在差旅系统中,减少行政摩擦。
  2. 行程控制在 30 天内且非就业。 用免签开展会议、考察、尽职调查、参展;若涉及派驻、培训或现场作业,请使用相应的工作签证或商务(M)签证,避免以免签”打擦边球”。
  3. 携带目的佐证。 中文邀请函及预订记录可顺畅边检,也便于后续申请停留证件;建议由境内实体统一出具邀请函模板。
  4. 关注有效期节点。 当前免签于 2026 年 12 月 31 日到期(俄罗斯至 2027 年)。年末出行前留意下一轮延期公告,必要时预留签证办理缓冲。
  5. 必要时与过境免签搭配。 非清单国家旅客(如不在单方面免签名单内的美国)仍可就真实中转行程使用 240 小时过境免签,二者互补而非互斥。
  6. 长期派驻另作安排。 免签不是居留或就业通道;长期停留须走标准的工作许可与居留许可流程,提前规划以避免身份真空。

相关阅读

  • 240 小时过境免签(79 号文)——需联程票、限口岸的通道,适合真实中转行程。
  • 区域性入境免签(173 号文)——海南、邮轮、东盟旅游团入境,适合目的地型旅游。
  • 外交部领事常见问题解答及互免签证协定一览表,获取最新国家更新与互免范围。

如需判断某位外籍员工适用哪条通道,可先按其国籍对照本文 50 国清单;不在清单内者,再评估是否满足 240 小时过境免签或区域性免签条件。三层通道叠加,已能覆盖绝大多数短期来华场景。

Sources

China’s 2026 Exit-Entry Administration Rules: What Foreign Employers Must Prepare For

  • On 31 July 2026 the State Council published the Regulations on Exit-Entry Administration (State Council Order No. 841), effective 15 September 2026, a 19-article set of rules supplementing the Exit-Entry Administration Law.
    2026年7月31日,国务院公布《国务院关于出境入境管理的规定》(国务院令第841号),自2026年9月15日起施行,共19条,是对《出境入境管理法》的补充配套规定。
  • The Regulations require that the stated purpose of any exit-entry, stay or residence application be genuine and lawful; immigration authorities may refuse to issue documents or deny entry where false materials or false statements are provided.
    《规定》要求出境入境、停留居留的申请事由必须真实、合法;提供虚假材料、作出虚假陈述的,移民管理机构、签证机关有权不予签发出入境证件或不准其出境、入境。
  • A filing (recordal) system is introduced for exit-entry intermediary agencies: agencies must file with the local immigration authority within 15 days of establishment, and existing agencies within 90 days of the Regulations taking effect.
    《规定》对出境入境中介服务机构实行备案管理:机构应自设立之日起15日内向所在地移民管理机构备案;《规定》施行前已从事中介服务的机构,应在施行之日起90日内办理备案。
  • Overseas enterprises and institutions may not provide exit-entry intermediary services in China; lawfully established foreign-invested and Hong Kong, Macao and Taiwan-invested entities in China may.
    境外企业、机构不得在中国境内提供出境入境中介服务;在中国境内依法设立的外资和港澳台资企业、机构可以依法从事出境入境中介服务。
  • The rules add clear grounds for barring entry of foreigners who submit false materials, make false statements, or were punished for border-control offences, and strengthen anti-sanction and counter-intervention legal linkage.
    《规定》明确外国人在境外申请中国签证或在口岸申请入境时提供虚假材料、虚假陈述,或因妨害国(边)境管理受到刑事处罚的,依法不准其入境,并强化反制裁、反干预的法律衔接。
  • For foreign-invested enterprises, the key shift is towards verified, substantive compliance: HR, legal and business teams should jointly verify the purpose, position and itinerary behind visa applications instead of delegating everything to agents.
    对外资企业而言,关键变化在于转向核验式、实质性合规:人力资源、法务与业务部门应共同核实签证申请背后的事由、岗位与行程,而非将一切交给代理机构。
  • The Regulations also protect commercial secrets, personal privacy and personal information handled by agencies and authorities, giving foreign companies clearer legal safeguards for employee data.
    《规定》同时保护主管部门及中介机构处理过程中的商业秘密、个人隐私与个人信息,为外资企业员工数据提供了更清晰的法律保障。

China’s 2026 Exit-Entry Administration Rules: What Foreign Employers Must Prepare For | 中国2026年出境入境管理新规:外资雇主必须准备什么

Why this matters now

On 31 July 2026, the State Council published the Regulations on Exit-Entry Administration (State Council Order No. 841), a compact 19-article regulation that takes effect on 15 September 2026. It sits under the Exit-Entry Administration Law of 2013 and responds to a specific set of problems identified by the authorities: rising safety risks for Chinese citizens travelling abroad, foreign applicants submitting false materials, and a murky intermediary-services sector. The timing is significant — China’s immigration authorities processed 369 million border crossings in the first half of 2026, up 10.8% year on year, an all-time high. For foreign-invested enterprises (FIEs), the regulation matters because it reshapes how visas and residence permits are verified, how intermediaries are regulated, and what employers must do to keep expatriate mobility compliant.

What the new rules change

The Regulations make three adjustments that matter to foreign employers. First, purpose verification is tightened: the stated purpose of an application for entry, stay or residence must be genuine and lawful, and applicants must cooperate when immigration authorities or visa offices verify identity and purpose. Individuals and entities that issue invitation letters or other supporting materials bear responsibility for their authenticity. This is a direct signal that “invitation letter” shortcuts and decorative job descriptions will no longer survive scrutiny. Second, a filing system is created for exit-entry intermediary agencies. Agencies must file with the local immigration authority within 15 days of establishment; those already operating must file within 90 days of the regulation taking effect. Third, the rules enlarge the reasons for denying entry to foreigners — covering false materials, false statements, and prior criminal punishment for obstructing border control — and explicitly strengthen the legal basis for counter-sanctions and counter-interference, giving Chinese authorities tools that can in principle affect individuals connected to foreign restrictive measures.

What this means for intermediary management

The intermediary filing regime is new and directly relevant to companies using visa agents. Under the rules, overseas enterprises and institutions may not provide exit-entry intermediary services in China, while lawfully established foreign-invested and Hong Kong, Macao and Taiwan-invested entities may. Intermediaries must meet conditions including staff with relevant professional knowledge, premises and funding; they may not publish false information, engage in exaggerated or misleading promotion, provide or assist in providing false materials, or help others improperly obtain visas, stay/residence documents or passports. Penalties include fines of RMB 20,000 to 50,000, suspension of operations and revocation of licences, with responsible individuals pursued. For FIEs, this means due diligence on your agent: confirm it is a licensed domestic entity, verify its filing, and require it to refuse obviously false applications.

Practical steps for foreign employers

  1. Jointly verify application substance. For every work visa, residence permit or short-term business visit, have HR, legal and the hiring department confirm the genuine purpose, position, dates and itinerary before submission; keep supporting evidence on file.
  2. Audit your invitation process. If your entity issues invitation letters, standardise who can sign them, what documents must back them, and how authenticity is checked.
  3. Re-check your visa agent. Confirm the intermediary is a lawfully established domestic entity (including FIE/HK-Macao-Taiwan-invested where applicable), has filed under the new rules, and will refuse false-material requests.
  4. Plan for longer lead times. Because material review is stricter, expect longer processing windows for visas and permits; build buffer into travel and onboarding schedules.
  5. Prepare for the September 2026 transition. Existing intermediary relationships should be re-documented by the 90-day filing deadline; update HR policies and employee handbooks for the new authenticity requirements.
  6. Protect employee data. Review how visa application data flows through your agent and intermediaries, and confirm confidentiality measures align with the regulation’s protections for personal privacy and information.

Risks and compliance notes

The regulation’s emphasis on authenticity means the biggest risk is the “rubber-stamp” application: an invitation letter that does not match a real job, a position title inflated for visa purposes, or a declared itinerary that no one intends to follow. These now carry refusal and, for intermediaries, penalty consequences. Companies should also note the counter-sanctions linkage — entities or individuals connected to foreign restrictive measures against China may face entry bars, so global mobility planning should account for geopolitical exposure. Finally, the 24-hour lodging registration duty, visa-free transit rules and this regulation work together; an employer that treats them as separate workstreams is more likely to miss a deadline than one that coordinates immigration, HR and legal.


中国2026年出境入境管理新规:外资雇主必须准备什么

为什么当下重要

2026年7月31日,国务院公布《国务院关于出境入境管理的规定》(国务院令第841号),这是一部精炼的19条行政法规,自2026年9月15日起施行。它以2013年《出境入境管理法》为基础,回应主管部门认定的几类具体问题:中国公民出境安全风险上升、少数外国人提交虚假材料、中介服务行业底数不清。时机意义显著——2026年上半年,全国移民管理机构查验出入境人员3.69亿人次,同比上升10.8%,创历史新高。对外资企业而言,这部规定之所以重要,在于它重塑了签证与居留许可的核验方式、中介的监管方式,以及雇主为保持外派人员流动合规必须做的工作。

新规改变了什么

《规定》做出三项对外资雇主有实际影响的调整。第一,事由核验收紧:申请入境、停留居留的事由必须真实、合法,申请人须配合移民管理机构、签证机关核实身份与事由;出具邀请函件或其他申请材料的单位或个人对真实性负责。这是一个直接信号——”邀请函”捷径与装饰性岗位描述将不再经得起审查。第二,对出境入境中介服务机构建立备案制度:机构应自设立之日起15日内向所在地移民管理机构备案;已经从事中介服务的,应在规定施行之日起90日内办理备案。第三,扩大外国人不准入境的情形——覆盖虚假材料、虚假陈述、因妨害国(边)境管理受到刑事处罚——并明确强化反制裁、反干预的法律基础,为相关部门提供了原则上可影响与外国限制性措施相关人员的工具。

对中介管理意味着什么

中介备案制度是全新的,与使用签证代理的企业直接相关。依规,境外企业、机构不得在中国境内提供出境入境中介服务;在中国境内依法设立的外资和港澳台资企业、机构可以依法从事。中介须具备条件,包括具有相关专业知识的工作人员、相适应的场地与资金保障;不得发布虚假信息、夸大或误导宣传、提供或协助提供虚假材料、协助他人违规办理签证、停留居留证件或护照。处罚包括2万元至5万元罚款、责令停业整顿、吊销证照,相关责任人员一并追责。对外资企业而言,这意味着要对代理做尽职调查:确认其为持牌境内实体、核验其备案、并要求其拒绝明显虚假的申请。

外资雇主的操作步骤

  1. 共同核验申请实质。 对每份工作签证、居留许可或短期商务访问,由人力资源、法务与用人部门在提交前共同确认真实事由、岗位、日期与行程,并存档支撑材料。
  2. 审计邀请流程。 如贵实体出具邀请函,规范谁可签署、需要哪些文件支撑、真实性如何核验。
  3. 复核签证代理。 确认中介为依法设立的境内实体(适用时包括外资及港澳台资),已按新规备案,并会拒绝虚假材料请求。
  4. 预留更长周期。 由于材料审查趋严,预计签证与许可办理窗口将拉长;为差旅与入职计划预留缓冲。
  5. 为2026年9月过渡做好准备。 现有中介关系应在90日备案截止日前重新文件化;按新真实性要求更新HR政策与员工手册。
  6. 保护员工数据。 审查签证申请数据在代理与中介间的流转,确认保密措施符合规定对个人隐私与信息的保护。

风险与合规提示

《规定》对”真实性”的强调意味着最大风险是”盖章式”申请:与真实岗位不符的邀请函、为签证目的虚高的职位头衔、或无人打算践行的申报行程。这些现在会导致拒签,并可能对中介产生处罚后果。企业还应注意反制裁联动——与针对中国的外国限制性措施相关的实体或个人可能面临入境限制,全球流动性规划应计入地缘政治敞口。最后,24小时住宿登记义务、过境免签规则与本规定相互配合;一个将三者割裂处理的企业,比一个将移民、HR与法务协同起来的企业更容易错过时限。

Sources

China’s Copyright Collective Management System (2026): What Foreign Rights Holders and Users Should Know

  • Copyright collective management lets a single licensed society exercise rights that individual rights holders cannot efficiently enforce themselves — performance, broadcasting, rental, information-network transmission and reproduction — and license users, collect royalties, and distribute them on the rights holder’s behalf.
    著作权集体管理由依法设立的集体管理组织,集中行使权利人难以自行有效行使的权利——表演权、广播权、出租权、信息网络传播权、复制权等,并以自己名义向使用者许可、收取使用费并向权利人转付。
  • Only organisations established under the Regulation on the Administration of Copyright Collective Management (State Council Decree No. 429) may conduct collective management; no other entity or individual may do so.
    只有依据《著作权集体管理条例》(国务院令第 429 号)设立的组织方可从事集体管理活动,其他任何组织和个人均不得从事。
  • A foreign or stateless rights holder can be covered in China through a mutual-representation agreement between a Chinese collective management organisation and its overseas counterpart, which must be filed with and announced by the national copyright authority.
    外国及无国籍权利人可通过中国集体管理组织与境外同类组织订立的”相互代表协议”获得覆盖,该协议须报国务院著作权管理部门备案并予以公告。
  • The licensing contract with a user cannot be exclusive, must be in writing, and is capped at two years (renewable); the organisation may not refuse a user who requests a licence on reasonable terms.
    与使用者订立的许可使用合同不得为专有许可、须以书面形式订立、期限不得超过 2 年(可续订);对以合理条件要求订立合同的,集体管理组织不得拒绝。
  • Royalties collected, after deducting management fees, must be paid in full to rights holders and may not be diverted; fee records must be kept for at least ten years and are open to inspection by rights holders and users.
    收取的使用费在提取管理费后须全部转付权利人、不得挪作他用;使用费转付记录须保存 10 年以上,权利人及使用者有权查阅。
  • The national copyright authority supervises organisations through annual audits, mandatory disclosure of fee schedules, and a 60-day deadline to investigate complaints from rights holders or users.
    国务院著作权管理部门通过年度审计、使用费收取标准公告公示以及对权利人/使用者举报 60 日内调查处理等制度实施监督。

China’s Copyright Collective Management System (2026): What Foreign Rights Holders and Users Should Know | 中国著作权集体管理制度(2026):涉外权利人与使用者须知

Why collective management exists

Many copyright rights are impractical for an individual creator or company to monitor and license one transaction at a time. Whoever owns the public-performance right to a song cannot realistically chase every café, shopping mall, radio station and streaming platform that plays it. China solves this through copyright collective management — a system in which a single licensed society, authorised by many rights holders, bundles their rights, licenses users centrally, collects royalties, and distributes them back. For a foreign-invested enterprise that either owns copyrighted works or uses music, text, software or broadcasts in its business, understanding this system is essential: it determines how you lawfully license background music, karaoke, online content, or how your own works get enforced and monetised in China.

The legal foundation

The system rests on the Regulation on the Administration of Copyright Collective Management (State Council Decree No. 429, effective 1 March 2005), issued under the Copyright Law. The regulation defines what collective management is, who may do it, how an organisation is set up, how it operates, and how it is supervised. Supplementary approval rules are maintained by the National Press and Publication Administration (which houses the National Copyright Administration, NCA). The key structural point: collective management is a closed, licensed monopoly — only organisations approved by the NCA may operate, and their business scopes must not overlap.

What rights can be collectively managed

Under the regulation, the rights that rights holders “find difficult to effectively exercise themselves” may be managed collectively. These include:

  • Performance right — public playing or singing of a work.
  • Projection/rendering right — showing a work in public by technical means.
  • Broadcasting right — wireless or wired broadcasting and rebroadcasting.
  • Rental right — renting out originals or copies of certain works.
  • Information-network transmission right — making a work available to the public over a network.
  • Reproduction right — among others that are hard to police individually.

These are precisely the rights that a foreign brand’s in-house legal team cannot practically police across thousands of venues or platforms — which is what makes collective management the practical enforcement channel.

How an organisation is established

Establishing a collective management organisation is a State-approved activity. The threshold conditions are specific:

  1. At least 50 rights holders发起设立 (as initiators).
  2. Its business scope must not cross or overlap with an already-registered organisation.
  3. It must be able to represent the relevant rights holders’ interests nationwide.
  4. It must have draft articles, a draft fee-collection standard, and a draft royalty-distribution method.

The applicant files with the NCA, which decides within 60 days whether to grant a Copyright Collective Management Licence. Within 30 days of approval, the applicant registers with the Ministry of Civil Affairs; within 30 days of registration, it files a copy of the registration certificate with the NCA, which announces the articles, fee standard and distribution method. The organisation must run its general assembly at least annually and maintain a council of no fewer than nine members.

How collective management works in practice

For a rights holder, the flow is:

  • Sign a collective management contract authorising the organisation to manage specified rights. The organisation may not refuse a qualified rights holder.
  • While the contract is in force, the rights holder generally may not itself exercise or license the contracted rights.
  • A rights holder may withdraw per the organisation’s rules; however, licences already granted to users remain valid until expiry, and the rights holder keeps entitlement to royalties from them.

For a user (say, a retailer playing music, a hotel offering video-on-demand, or a platform streaming content), the flow is:

  • The organisation must license on reasonable request and may not refuse or impose an exclusive licence.
  • The licence contract is in writing, capped at two years, renewable.
  • The user must provide usage data (titles, right-holder names, manner, quantity, time) unless the contract says otherwise; the organisation has a confidentiality duty over any trade secrets in that data.
  • The organisation must maintain a rights-information query system that both rights holders and users can consult.

Royalties and supervision

The economic safeguards are deliberately strict:

  • The organisation sets a fee-collection standard, which is announced by the NCA; royalties are then negotiated against that standard.
  • After deducting a management fee (which must decline as revenue rises), all remaining royalties must be paid to rights holders — none may be diverted.
  • The organisation must keep royalty-distribution records for at least ten years, and rights holders and users have a statutory right to inspect them.
  • Each year the organisation publishes an audited financial report.
  • The NCA supervises through on-site checks, account review, and attendance at key meetings, and must investigate complaints within 60 days. Rights holders may report refusals to license, mis-handled fees, or denied record access; users may report unlawful refusals to contract or failures to apply the announced fee standard.

What this means for foreign-invested enterprises

  • If you use copyrighted content in China — background music in stores, karaoke in F&B outlets, streaming or broadcast features in apps, or reproduction of texts/images — obtain licences through the relevant collective management organisation rather than assuming individual clearance covers public-performance or network-transmission scenarios. Keep your usage records; they are your defence against disputes and your input to royalty calculation.
  • If you own copyrights — music, literature, software, audiovisual works — you can join a Chinese collective management organisation, or, more commonly for foreign holders, be covered via a mutual-representation agreement between that organisation and your home-country society. File and confirm the agreement’s NCA备案/announcement so your coverage is recognised.
  • Plan for two-year licence cycles and budget royalties against the announced fee standards; treat the management-fee decline and full-distribution rules as your assurance that fees reach rights holders (including you, if you are one).
  • Watch the boundaries. The organisation cannot grant exclusive licences, cannot refuse reasonable requests, and cannot divert royalties. If you encounter such conduct as a user or rights holder, you have a statutory complaint route to the NCA.

Boundaries to keep in mind

Collective management covers only the rights assigned to it — it is not a blanket licence for all uses, and it does not replace direct licensing for rights outside its scope (e.g., translation, adaptation, or exclusive commercialisation you wish to control yourself). The mutual-representation route is the practical bridge for most foreign rights holders, but it depends on a valid, filed agreement. And because each organisation has a non-overlapping scope, identify the correct one for your specific right (performance, reproduction, network transmission, etc.) before engaging.


中国著作权集体管理制度(2026):涉外权利人与使用者须知

为何需要集体管理

许多著作权权利若由权利人逐笔监督与许可,在现实中几乎不可行。一首歌曲的公开表演权人,不可能逐一追查每一家咖啡馆、商场、广播电台与流媒体平台。中国的解决之道是著作权集体管理——由一家经许可的集体管理组织,获得众多权利人授权后将其权利打包,统一向使用者许可、集中收取使用费并分配回权利人。对于既可能拥有作品又可能使用音乐、文字、软件或广播内容的在华外资企业而言,理解这套制度至关重要:它决定了你如何合法取得背景音乐、卡拉 OK、线上内容的许可,也决定了你自己的作品在中国如何获得保护与变现。

法律基础

该制度建立在《著作权集体管理条例》(国务院令第 429 号,2005 年 3 月 1 日施行)之上,系依据《著作权法》制定。条例界定了集体管理的含义、主体资格、设立程序、运营规则与监督机制。补充性的审批规则由国家新闻出版署(加挂国家版权局牌子)维护。关键结构特征是:集体管理是一种封闭、经许可的专营——只有经国家版权局批准的组织方可运营,且其业务范围不得交叉、重合。

可纳入集体管理的权利

依条例,权利人”难以有效行使”的权利可由集体管理组织管理,主要包括:

  • 表演权——公开表演或演奏作品。
  • 放映权——通过技术手段公开再现作品。
  • 广播权——无线或有线方式广播及转播。
  • 出租权——出租特定作品原件或复制件。
  • 信息网络传播权——通过网络向公众提供作品。
  • 复制权——以及其他难以个别监管的权利。

这些恰恰是外资品牌自有法务团队难以在成千上万个场所或平台逐一维权的权利——这也正是集体管理成为实际维权通道的原因。

组织如何设立

设立集体管理组织属于行政许可事项,门槛明确:

  1. 发起设立的权利人不少于 50 人。
  2. 业务范围须与已登记组织不交叉、不重合。
  3. 须能在全国范围代表相关权利人利益。
  4. 须具备章程草案、使用费收取标准草案及使用费转付办法草案。

申请人向国家版权局提交材料,国家版权局自收到之日起 60 日内作出是否批准的决定;获批后 30 日内到民政部办理登记;登记证书核发后 30 日内将副本报国家版权局备案,由后者公告章程、收费标准与转付办法。组织须每年至少召开一次会员大会,理事会成员不少于 9 人。

集体管理的实际运作

对权利人而言,流程为:

  • 订立集体管理合同,授权组织管理特定权利;对符合条件的权利人,组织不得拒绝。
  • 合同有效期内,权利人一般不得自行行使或许可合同约定的权利。
  • 权利人可按章程退出;但已授予使用者的许可在期满前继续有效,权利人仍有权取得相应使用费。

对使用者(如在门店播放音乐的零售商、提供点播的酒店、流媒体平台)而言,流程为:

  • 组织必须按合理请求予以许可,不得拒绝,也不得订立专有许可。
  • 许可合同须为书面形式,期限不超过 2 年,可续订。
  • 使用者须提供使用数据(作品名称、权利人名称、使用方式、数量、时间等),合同另有约定除外;涉及商业秘密的,组织负有保密义务。
  • 组织须建立权利信息查询系统,供权利人与使用者查询。

使用费与监督

经济层面的保障十分严格:

  • 组织制定使用费收取标准,由国家版权局公告;使用费在该标准基础上协商确定。
  • 提取管理费(须随收入增加而逐步降低)后,剩余使用费须全部转付权利人,不得挪作他用。
  • 组织须编制并保存使用费转付记录至少 10 年,权利人与使用者有权查阅。
  • 组织每年须发布经审计的财务报告。
  • 国家版权局通过现场检查、账目核查、列席重要会议实施监督,并须在 60 日内调查举报事项。权利人可就拒绝许可、费用处理不当、拒绝提供记录等举报;使用者可就违法拒绝订约或未按公告标准收费等举报。

对在华外资企业的启示

  • 若你在中国境内使用受版权保护的内容——门店背景音乐、餐饮卡拉 OK、应用内的流媒体或广播功能、文字/图像复制等——应通过相关集体管理组织取得许可,而非想当然地认为个别授权已覆盖公开表演或网络传播场景。保留使用记录:既是争议抗辩依据,也是使用费计算的基础。
  • 若你拥有版权——音乐、文学、软件、视听作品——可加入中国集体管理组织;对境外权利人更常见的方式,是通过该组织与本国同类组织之间的相互代表协议获得覆盖。确认该协议已向国家版权局备案并公告,以便你的覆盖获得承认。
  • 规划 2 年许可周期,并依据公告的收费标准预算使用费;将管理费递减与全额转付规则视为费用最终到达权利人(包括你自身,若你也是权利人)的保障。
  • 注意边界。 组织不得授予专有许可、不得拒绝合理请求、不得挪用使用费。作为使用者或权利人若遇此类行为,依法可向国家版权局投诉。

须把握的边界

集体管理仅覆盖被授权给它的权利——并非对所有使用的一揽子许可,也不能替代对范围外权利(如翻译、改编或你希望亲自控制的独占商业化)的直接许可。相互代表协议是多数境外权利人最现实的桥梁,但它依赖一份有效且已备案的协议。又因各组织业务范围不重叠,在接洽前应确认针对你特定权利(表演、复制、信息网络传播等)的正确组织。

Sources

Software copyright registration in China for foreign firms (2026): the CPCC playbook

  • Computer software is protected automatically from completion under the Copyright Law, but registration with the China Copyright Protection Center (CPCC) is the evidentiary cornerstone for enforcement and pledge financing.
    计算机软件自开发完成依《著作权法》自动受保护,但向中国版权保护中心(CPCC)登记是维权与质押融资的证据基石。
  • From 15 March 2026 the CPCC upgraded the software copyright application form: the function description must be 500–1,300 characters, and the signature page adds a handwritten integrity statement plus ID number.
    自2026年3月15日起,版权中心升级软著申请表:软件主要功能须500–1300字,签章页新增手抄诚信声明与身份证号。
  • A new integrity system targets AI-generated code and batch ghostwriting: applicants must certify no AI was used to write code or documents, with a bad-faith list and credit-record penalties.
    新建诚信制度治理AI生成代码与批量代写:申请人须承诺未用AI编写代码或文档,违者列入失信名单并记入征信。
  • Foreign software firms may register through a China agent; overseas corporate documents need notarization, consular authentication and a certified Chinese translation.
    外国软件企业可委托中国代理登记;境外主体资格文件须公证、领事认证并附认证中文译本。
  • Registered software copyright can be pledged to domestic banks for credit in eight pilot provinces — turning intangible IP into working capital.
    已登记软件著作权可在八省试点向国内银行质押信贷,将无形IP转化为营运资金。
  • Three enforcement tracks — administrative, civil, criminal — all prioritize the CPCC registration certificate as ownership proof.
    行政、民事、刑事三轨救济均优先采信CPCC登记证书作为权属证明。
  • Global software and SaaS entrants should file within 3 months of China release and preserve source excerpts and Chinese operation manuals.
    全球软件与SaaS入华者应在国内发布后3个月内登记,并备妥源码节选与中文操作手册。

Software copyright registration in China for foreign firms (2026): the CPCC playbook | 外国企业的软件著作权登记(2026):中国版权保护中心实操手册

Overview: copyright, not patent, for code

For foreign software, SaaS and game developers entering China, the default protection for source and object code is copyright, not patent. Under the Copyright Law (2020 amendment), computer software is an enumerated work type, and protection arises automatically upon completion — no registration required to exist. Yet in practice, registration with the China Copyright Protection Center (CPCC, 中国版权保护中心) is decisive: it is the preliminary proof of ownership accepted across administrative, civil and criminal enforcement.

The legal basis

The Copyright Law of the PRC lists computer software as a protected work and grants authors publication, authorship, modification, reproduction, distribution, rental, information-network dissemination, translation and other rights, with punitive damages for infringement. The Regulations on the Protection of Computer Software (State Council Decree No. 339) provide the dedicated regime: software copyright arises on completion; registration is voluntary but the certificate is prima facie evidence of the registered matters. The CPCC is the national registration and copyright-pledge authority.

The 15 March 2026 upgrade

On 15 March 2026 the CPCC announced an optimized software copyright application form, effective immediately, with the old form retired the same day. Two changes matter for applicants:

  • Function description lengthened from “under 200 characters” to a required 500–1,300 characters, demanding a complete, detailed account of R&D background, core architecture, function modules, technical implementation and application scenarios — curbing templated, thin filings.
  • Signature page integrity additions: a handwritten statement that the applicant did not use AI to develop/write code, draft documents or generate application materials, plus the agent’s signature and ID number, pressing applicant accountability and targeting the “AI-code + batch-filing” gray market.

The new integrity system and AI scrutiny

Alongside the form, the CPCC established a software copyright application integrity system with a bad-faith penalty mechanism. False materials, abnormal filings and malicious repeated applications are sanctioned under a “trust rewarded, bad faith restricted” framework. Agencies face tighter supervision; template filings, batch ghostwriting and false certifications are cleaned up. Applicants and agencies that submit AI-generated code or documents face dual penalties, and serious offenders enter a copyright bad-faith list and a personal credit record.

Foreign-firm filing route

A foreign enterprise with no establishment in China files through a duly established China copyright agent. Required materials typically include the application form, identification of the software (source-code excerpts and documentation), and proof of ownership/assignment. Overseas corporate documents, developer assignment agreements and authorization papers must be notarized, consular-authenticated, and accompanied by a certified Simplified-Chinese translation — archive the authenticated hard copies for litigation. Keep daily development logs, developer contracts and version records to supplement ownership if the certificate is challenged.

Enforcement: three tracks, one proof

China offers a three-tiered, dual-track enforcement system for software piracy:

  • Administrative: local NCAC (国家版权局) branches conduct inspections, confiscate cracked copies and tools, and fine from CNY 100 per pirated copy up to CNY 200,000 for circumvention — fast (1–2 months) with lower evidence thresholds.
  • Civil: right holders may seek pre-litigation injunctions and claim actual losses or statutory damages up to CNY 5 million per infringement, plus attorney and notarization costs.
  • Criminal: large-scale commercial piracy triggering copyright-infringement crimes draws fines and imprisonment for operators of cracking platforms and bulk distributors.

All three prioritize the CPCC registration certificate as core ownership proof; unregistered software struggles to enforce.

Pledge financing: IP into capital

A unique advantage of registration: under the Measures for Copyright Pledge Registration, registered software property rights can be pledged to domestic banks for credit via CPCC pledge filing. Foreign software enterprises with completed China registration may join national copyright-finance pilots across eight major provinces, converting intangible software IP into operating capital without fixed-asset collateral. Unregistered software cannot undergo valid pledge registration.

Practical steps for global software entrants

  1. File CPCC registration within 3 months of official China release.
  2. Prepare source excerpts and a Chinese operation manual meeting identification standards.
  3. Authenticate and translate all overseas corporate and assignment documents before filing.
  4. Separate ideas from code in R&D records; retain logs and contracts.
  5. File administrative complaints promptly when cracked copies appear, submitting the certificate for fast takedowns.
  6. Use pledge registration post-certificate to access IP-backed loans in pilot regions.

Related reading

Foreign companies’ general copyright registration, national treatment and the Apostille shortcut are covered in a separate article; this piece is the software-copyright briefing plus the action list.


外国企业的软件著作权登记(2026):中国版权保护中心实操手册

概览:代码靠著作权,而非专利

对外国软件、SaaS与游戏开发者入华而言,源代码与目标代码的默认保护是著作权而非专利。依2020年修正的《著作权法》,计算机软件列为受保护作品类型,保护自开发完成自动产生——无需登记即存在。但实践中,向中国版权保护中心(CPCC)登记具有决定性:它是行政、民事、刑事三轨救济均采信的权属初步证明。

法律依据

《中华人民共和国著作权法》将计算机软件列为受保护作品,赋予发表、署名、修改、复制、发行、出租、信息网络传播、翻译等权利,侵权引入惩罚性赔偿。《计算机软件保护条例》(国务院令第339号)提供专门制度:软件著作权自完成产生;登记自愿,但登记证书是登记事项的初步证明。版权中心为国家级登记与著作权质权登记机构。

2026年3月15日的升级

2026年3月15日,版权中心宣布优化后的软著申请表即时施行,旧表同日停用。两项变化关乎申请人:

  • 功能描述由”200字以内”提至须500–1300字,要求完整详实说明研发背景、核心架构、功能模块、技术实现与应用场景——遏制模板化、简略填报。
  • 签章页诚信增补:新增手抄声明,承诺申请人未使用AI开发编写代码、撰写文档或生成申请材料,并附经办人签名与身份证号,压实主体责任,直指”AI代码+批量申请”灰色产业链。

新建诚信制度与AI审查

随表单升级,版权中心建立软件著作权登记申请诚信制度并引入失信惩戒机制。对虚假材料、非正常申请、恶意重复申报在”守信便利、失信受限”框架下制裁。代理机构受更严监管;模板申报、批量代写、虚假承诺被清理。提交AI生成代码或文档的申请人及代理机构面临双处罚,严重者列入版权登记失信名单并记入个人征信。

外国企业登记路径

在中国无机构的外国企业须委托依法设立的中国版权代理机构办理。材料通常包括申请表、软件鉴别材料(源码节选与文档)及权属/转让证明。境外主体资格文件、开发者转让与授权协议须公证、领事认证并附认证中文译本——将认证纸质件归档备诉。保留每日开发日志、开发者合同与版本记录,以备证书受挑战时补强权属。

救济:三轨一证

中国对软件盗版提供三级双轨救济:

  • 行政:地方版权局(国家版权局系统)实地检查、没收破解副本与工具,对规避技术措施处以每件100元至20万元罚款——1–2个月快速、证据门槛较低。
  • 民事:权利人可申请诉前禁令,主张实际损失或法定赔偿每案最高500万元,外加律师费与公证费。
  • 刑事:大规模商用盗版构成侵犯著作权罪的,对破解平台运营者与批量分销者判处罚金与有期徒刑。

三轨均优先采信CPCC登记证书作为核心权属证明;未登记软件难以维权。

质押融资:IP变资本

登记独有优势:依《著作权质权登记办法》,已登记软件财产权可经版权中心质押备案向国内银行信贷。完成中国登记的外国软件企业可参与八省国家版权金融试点,将无形软件IP转化为无需固定资产抵押的营运资金。未登记软件无法进行有效质押登记。

全球软件入华者的实操步骤

  1. 国内发布后3个月内完成CPCC登记。
  2. 备妥源码节选与中文操作手册,满足鉴别材料标准。
  3. 登记前公证、认证并翻译所有境外主体与转让文件。
  4. 研发记录中分离思想与代码,留存日志与合同。
  5. 破解副本出现即行政投诉,提交证书以快速下架。
  6. 获证后利用质押登记,在试点地区获取IP质押贷款。

延伸阅读

外国企业在华著作权登记、国民待遇与海牙认证捷径本站另有专文;本文为软件著作权简报加行动清单。

Sources

Franchising in China Gets a Judicial Roadmap: SPC’s 2026 Typical Cases for Foreign Brands

  • On 12 August 2026 the Supreme People’s Court released seven typical cases on commercial franchising (jia meng lian suo), clarifying how courts characterise franchise relationships, protect franchisees and sanction franchisor misconduct.
    2026年8月12日,最高人民法院发布7件商业特许经营典型案例,明确了法院如何认定特许经营法律关系、保护被特许人权益并规制特许人违法行为。
  • Courts apply a substance-over-form test: split or disguised contracts that together exhibit the hallmarks of franchising — licensed business resources, a unified business model and payment of fees — will be treated as franchise agreements.
    法院采取穿透实质的认定原则:即使合同被拆分或包装,只要共同具备”许可经营资源、统一经营模式、支付特许经营费用”三大特征,即认定成立特许经营关系。
  • Franchisees enjoy a statutory “cooling-off” right: they may unilaterally rescind the contract within a reasonable period before the licensed resources are actually used, even without an express contract clause.
    被特许人享有法定”冷静期”单方解除权:在经营资源尚未被实际利用的合理期限内,即使合同未明确约定,也可以单方解除合同。
  • A franchisor that engages in false advertising to induce the franchisee loses the contract on fraud grounds; unqualified individuals and entities that grant franchises face void or invalid contracts.
    特许人以虚假宣传诱使被特许人订立合同的,构成欺诈、合同可撤销;不具备特许人法定资格的主体签订的特许经营合同被认定无效。
  • Franchisors operating without the “two outlets, one year” track record can be penalised by commerce authorities, and the courts will uphold those administrative penalties.
    特许人不具备”两店一年”条件违规开展特许经营的,商务主管部门可予以行政处罚,人民法院依法支持。
  • For foreign brands entering China, the case law sets a compliance benchmark for franchise documentation, disclosure, cooling-off clauses and administrative filing — and signals tougher judicial scrutiny of “routine franchising” traps.
    对入华外资品牌而言,该批案例为加盟合同文本、信息披露、冷静期条款与行政备案树立了合规基准,也预示着对”套路加盟”更严格的司法审查。
  • Foreign franchisors should also map franchise exposure onto trademark law: brand resources, trade secrets and licensing terms sit at the core of what courts examine.
    外资特许人还须将加盟业务与商标法规则对接:商标资源、商业秘密与许可条款正是法院审查的核心。

Franchising in China Gets a Judicial Roadmap: SPC’s 2026 Typical Cases for Foreign Brands | 中国特许经营获司法路线图:最高法2026年典型案例对外资品牌的启示

Why this matters now

Commercial franchising — the “jiameng lian suo” model used by restaurants, retail, hotels, education and quick-service brands — has grown rapidly in China, and so have its disputes. On 12 August 2026 the Supreme People’s Court (SPC) released seven typical cases on commercial franchising, published through the court’s official channels and covered by Xinhua and other state media. For foreign brands that license their trademarks and business systems to Chinese franchisees, the release is a practical compliance readout: it shows how Chinese courts will characterise a franchise deal, what obligations sit on the franchisor, and where the enforcement risk concentrates. The cases also matter because China’s franchise market is one of the few in Asia where brand licensing at scale is subject to both the Commercial Franchise Administration Regulations and increasingly active judicial interpretation.

What the typical cases establish

The seven cases address four clusters of issues. First, contract characterisation: a company that signed a “service agreement” plus a “project logo use agreement” to avoid the franchise label still had the relationship re-characterised as a franchise because the contracts together gave the franchisee the use of business resources under a unified model for a fee. Second, franchisee protection: a franchisee who paid fees but had not yet used the business resources could exercise the statutory cooling-off right and rescind the contract, entitling them to a refund. Third, franchisor obligations: a franchisor that engaged in false advertising to induce a franchisee was found to have committed fraud, so the contract could be rescinded; a franchisor whose filing qualification was revoked mid-contract was vulnerable to termination; and an individual or entity without franchisor qualifications could not grant valid franchises. Fourth, enforcement: franchisors without the “two outlets, one year” requirement were penalised by commerce authorities, and the courts upheld the penalties; fraud and pyramid-like conduct in the franchise space was channelled into criminal liability where elements were met.

What this means for foreign franchisors

For a foreign trademark owner entering China through a master franchise or joint-venture franchise structure, the cases carry several operational lessons. Documentation matters: the more your contracts package themselves as technology services or brand-use licenses, the more likely a court will look through the form and apply franchise law anyway — so draft for the franchise regime from the start. Disclosure discipline matters: China’s franchise regulations require disclosure of registered trademarks, business model and related information before signing; the new cases reinforce that non-disclosure and over-promotion are not just administrative risks but contract risks. Cooling-off design matters: because the statutory right exists even without a clause, franchise systems should budget for early exits before the franchisee actually starts using the brand. Finally, qualification checks matter: before granting a franchise, verify the franchisee-facing entity structure, and ensure the “two outlets, one year” record and the Ministry of Commerce filing are genuinely in place, because both are now judicially tested.

Practical steps for foreign brands

  1. Audit your franchise documents. Review franchise agreements, disclosure statements and marketing materials against the substance-over-form test, and decide explicitly whether to operate under the franchise regime or another model.
  2. Reinforce disclosure. Update the disclosure document to reflect the latest trademark registrations, royalties and financial projections; keep a dated record of delivery to each franchisee.
  3. Handle the cooling-off window. Set procedures to process early rescission claims within the “not yet used” window, including refund mechanics and brand-asset recovery.
  4. Verify qualifications. Confirm the franchisor entity’s “two outlets, one year” experience and its Ministry of Commerce filing; document both before signing new franchisees.
  5. Train sales staff. Ensure marketing teams avoid absolute promises about profitability and success, since over-promotion can convert an administrative case into a fraud rescission.
  6. Coordinate IP and dispute teams. Keep trademark and trade-secret evidence ready, because in disputes the courts examine the licensed resources first; integrate franchise case law into your China dispute playbook.

Risks and compliance notes

The judicial signal is stricter than before: courts will pierce contract form, uphold franchisee rescissions, and back administrative penalties. Foreign franchisors should treat the “two outlets, one year” rule and the filing obligation as structural, not clerical. If a brand is expanding through area development agreements or sub-franchising, confirm that liability allocation between the foreign licensor and the Chinese master franchisee is clear, because in substance-over-form review the foreign brand’s trademarks are usually the core licensed resource. Finally, cross-border licensing itself touches tax withholding and IP registration; the franchise contract’s fee structure should be reviewed alongside trademark licence recordation to keep the whole structure consistent.


中国特许经营获司法路线图:最高法2026年典型案例对外资品牌的启示

为什么当下重要

商业特许经营——餐饮、零售、酒店、教育培训与快餐品牌普遍采用的”加盟连锁”模式——在中国增长迅速,纠纷也随之增多。2026年8月12日,最高人民法院发布7件商业特许经营典型案例,通过法院官方渠道发布,新华社等中央媒体广泛报道。对向中国加盟商许可商标与经营体系的境外品牌而言,该批案例是一次实用的合规读本:它展示了中国法院将如何认定加盟交易、特许人承担哪些义务、执法风险集中在何处。案例之所以重要,还因为中国是亚洲少数几个规模化品牌授权既受《商业特许经营管理条例》约束、又面临日益活跃的司法解释的市场之一。

典型案例确立了什么

7件案例围绕四组问题展开。一是合同定性:某公司签订《服务协议书》加《项目标识使用协议》以规避加盟标签,但由于合同共同赋予加盟商在统一模式下使用经营资源并支付对价,仍被重新认定为特许经营关系。二是被特许人保护:已付费但尚未实际使用经营资源的被特许人可以行使法定”冷静期”解除权并解除合同、获得退款。三是特许人义务:以虚假宣传诱使加盟商签约的特许人被认定构成欺诈、合同可撤销;合同履行期间备案资格被撤销的特许人更易被解除合同;不具备特许人资格的主体不能签订有效加盟合同。四是执法衔接:不具备”两店一年”条件的特许人被商务主管部门处罚,法院予以支持;加盟领域构成诈骗、传销要件的,移送刑事责任追究。

对外资特许人的意义

对外国商标权人通过主加盟或合资加盟结构进入中国而言,该批案例带来若干操作性启示。文件文本很重要:合同越是将自己包装成技术服务或品牌使用许可,法院越可能穿透形式、仍然适用加盟法规——因此应从设计之初就按特许经营体制起草。信息披露纪律很重要:中国加盟法规要求在签约前披露注册商标、经营模式及相关信息;新案例强化了”不披露与过度宣传不仅是行政风险,更是合同风险”。冷静期设计很重要:由于即使无条款约定也存在法定权利,加盟体系应为加盟商真正开始使用品牌之前的早期退出预留预算。资格核查很重要:授予加盟权前,应核验面向加盟商的实体结构,并确保”两店一年”业绩与商务部备案真实到位——因为二者现在都经受司法检验。

外资品牌的操作步骤

  1. 审计加盟文件。 对照”穿透实质”测试审查加盟协议、信息披露书与营销材料,并明确决定是按特许经营体制运营还是采用其他模式。
  2. 强化信息披露。 更新披露文件以反映最新商标注册、特许费与财务预测;留存向每位加盟商交付披露文件的带日期记录。
  3. 处理冷静期窗口。 建立程序,在”尚未实际使用”窗口内处理早期解约请求,包括退款机制与品牌资产回收。
  4. 核验资质。 确认特许人实体的”两店一年”经验与商务部备案;在签约新加盟商前将二者文件化。
  5. 培训销售团队。 确保营销团队避免对盈利能力与成功作出绝对承诺,因为过度宣传可能把行政案件变成欺诈撤销案件。
  6. 协同知识产权与争议团队。 准备好商标与商业秘密证据,因为争议中法院首先审查许可的经营资源;将加盟案例法纳入中国争议应对手册。

风险与合规提示

此次司法信号比以往更严:法院将穿透合同形式、支持被特许人解除合同、并支持行政处罚。外资特许人应把”两店一年”规则与备案义务视为结构性要求而非事务性要求。如果品牌正通过区域开发协议或再加盟扩张,应确认外国许可人与中国主加盟商之间的责任分配清晰,因为在穿透实质审查中,外资品牌的商标通常正是被许可的核心资源。最后,跨境许可本身还涉及预提税与知识产权备案;加盟合同费用结构应与商标许可备案一并审查,以保持整体结构一致。

Sources